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3 OBJECTIVES 
 
The human large intestine is colonized by a dense and complex community 
composed largely of anaerobic bacteria [FLINT et al., 2007]. This large and 
diverse microbiota is recognized as contributing to gut maturation, host nutrition 
and pathogen resistance. Moreover, microbes have been shown to regulate 
intestinal epithelial proliferation, host energy metabolism and inflammatory 
immune responses [DETHLEFSEN et al., 2006]. Additionally, the main 
functions of the microbiota include the fermentation of non-digestible dietary 
residue and endogenous mucus, salvage of energy as short-chain fatty acids 
(SCFAs), production of vitamin K and absorption of ions [GUARNER et al., 
2003]. 
 
As mentioned above, the human gut microbiota plays several significant roles in 
the metabolism of nutrients. On the other hand, the composition of gut 
microbiota can be modulated by host, environment, bacterial factors and diet 
may exert a major effect on the composition and activity of the gut microbiota. 
Strong evidence has emerged of substantial modifications during illness 
(chronic and degenerative diseases including inflammatory bowel disease, 
Crohn’s disease, colon cancer and rheumatoid arthritis) or exposure to 
threatening experiences, such as antibiotics and chemotherapy [THOMPSON-
CHAGOYAN et al., 2007]. Evidence support the potential role of the gut 
microbiota in the development of obesity and explore the role that modifying the 
gut microbiota may play in its future treatment, as obesity is a major health 
problem because of its serious health consequences including type 2 diabetes 
and cardiovascular diseases [DIBAISE et al., 2008]. 
 
Diet-derived substrate, particularly undigested fibre and starch reaching the 
large intestine, have major effects upon bacterial community structure and 
metabolism in the colon. SCFAs formed by microbial fermentation have an 
important effect on colonic health. Butyrate in particular provides a potentially 
important link between diet and colonic health [BARCENILLA et al., 2000]. 
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With ageing, a decrease in beneficial organisms such as Lactobacilli and 
Bifidobacteria and an increase in the number of facultative anaerobes have 
been reported. This, along with a general reduction in species diversity, 
changes to diet and altered digestive physiologies such as intestinal transit 
time, may result in increased gastrointestinal discomfort and a greater 
susceptibility to disease [ZWIELEHNER et al., 2009]. 
 
Even if chemotherapy and antibiotics are used for combating life-threatening 
diseases, treatment with antibiotics and chemotherapy may result in shifts of the 
human microbiota associated with side-effects like diarrhoea, constipation and 
malnutrition. The altered balance of the microbiota potentially leads to 
Clostridium difficile infections, a common colonizer of the human gut whose 
growth is held in check by the normal biota but which overgrows the biota upon 
antibiotic use and chemotherapeutic treatment. Because of these changes, 
absorption and other intestinal functions involving the microbiota are altered 
[CROSWELL et al., 2009, GIBSON et al., 2006, SCHALK et al., 2009]. 
 
Altogether, the microbiota seems to be one of the most complex ecosystems 
with a multitude of capacities as interacting with diet and the human host, 
moving the focus of this diploma thesis on the human microbiota. In particular, 
this thesis should give an overview of the topics mentioned above: microbiota 
and butyrate, the ageing microbiota and the microbiota in times of 
chemotherapy and antibiotic treatment.  
 
The manuscripts titled “Changes in human faecal microbiota due to 
chemotherapy analyzed by TaqMan-PCR and PCR-DGGE fingerprinting” by 
Lassl et al., “Consequences of diet and ageing for individual SCFAs and faecal 
microbiota” by Hippe et al. and the already published article “Combined PCR-
DGGE fingerprinting and quantitative-PCR indicates shifts in faecal population 
sizes and diversity of Bacteroides, Bifidobacteria and Clostridium cluster IV in 
industrialized elderly” by Zwielehner et al. can be found in the appendix of this 
thesis. The author of this thesis participated in writing and working on the 
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manuscript by Hippe et al. and the published research article by Zwielehner et 
al., but the main focus of this diploma thesis is on analyzing the microbiota 
during chemotherapy and antibiotic treatment.  
 
The purpose of this thesis was to analyze the course of faecal microbiota of 
patients receiving cancer chemotherapy ± antibiotics in comparison to healthy 
control individuals. The focus was on abundance and diversity of dominant 
bacteria, Bacteroides, bifidobacteria, Clostridium cluster IV, Clostridium cluster 
XIVa and Clostridium difficile using culture-independent methods. Changes in 
populations were analyzed for the ability to return to its original composition 
(resilience) after chemotherapy and the emergence of Clostridium difficile. 
 
4 INTRODUCTION 
 
4.1 MICROBIOTA AND HOST 
The adult human intestine is home to an almost inconceivable number of 
microorganisms [BACKHED et al., 2005]. The microorganisms that live inside 
and on humans (known as the microbiota) are estimated to outnumber human 
somatic and germ cells by a factor of ten. Together, the genomes of these 
microbial symbionts (defined as the microbiome) provide traits that humans did 
not need to evolve on their own [TURNBAUGH et al., 2007]. Therefore, our gut 
microbiota can be pictured as a microbial organ placed within a host organ 
[BACKHED et al., 2005]. 
 
The gut microbiome encodes metabolic capacities that remain largely 
unexplored but include (1) the degradation of otherwise indigestible 
components of our diet [TURNBAUGH et al., 2009], (2) protection against 
epithelial cell injury, (3) regulation of host fat storage [ECKBURG et al., 2005], 
(4) vitamin synthesis and (5) generation of short-chain fatty acids 
[TLASKALOVA-HOGENOVA et al., 2004]. Moreover, a healthy microbiota plays 
significant roles in the immunopotentation and prevention of colonization by 
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pathogens in the gastrointestinal tract and hence is involved in maintaining 
human health [DE LA COCHETIERE et al., 2005]. 
 
We know that the composition of the GI microbiota is highly distinct between 
individuals and many factors, such as diet, host genotype and microbial 
interactions seem to be able to explain the diversity and the individuality of 
these communities [DETHLEFSEN et al., 2006]. Despite this variability, there 
appear to be ‘core species’ present in a majority of humans which are quite 
resilient to external influences and ‘passengers’ or transients, sometimes in 
great numbers, sometimes below detection limits [ZWIELEHNER et al., 2009]. 
 
Our knowledge of the composition of the adult gut microbiota mainly stems from 
culture-based studies [BACKHED et al., 2005], but due to insensitivity of 
cultivation, in the last decades investigators have begun to explore this 
ecosystem using molecular fingerprinting methods and sequence analysis of 
cloned 16small-subunit ribosomal RNA (16S rRNA) genes [ECKBURG et al., 
2005].  
4.2 MICROBIOTA IN HEALTH AND DISEASE 
The composition of gut microbiota can be modulated by host, environment, and 
bacterial factors and strong evidence has emerged of substantial modifications 
during illness or exposure to threatening experiences and medical treatment. 
Alterations in gut microbiota and their functions have been widely associated 
with many chronic and degenerative diseases including inflammatory bowel 
disease, colon cancer and rheumatoid arthritis. [THOMPSON-CHAGOYAN et 
al., 2007]. 
 
Crohn’s disease, ulcerative colitis, and pouchitis are the result of continuous 
microbial antigenic stimulation of pathogenic immune responses as a 
consequence of host genetic defects in mucosal barrier function, innate 
bacterial killing, or immunoregulation. Altered microbial composition and 
function in inflammatory bowel disease result in increased immune stimulation, 
epithelial dysfunction, or enhanced mucosal permeability [SARTOR, 2008]. 
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Correlations between the gastrointestinal microbiota and diseases like 
allergenicity [SHREINER et al., 2008], autoimmune diseases [TLASKALOVA-
HOGENOVA et al., 2004] and individual dispositions such as obesity [ZHANG 
et al., 2009] have been discussed. 
Under normal conditions, the gut microbial ecosystem is quite stable and 
humans are protected against infections by their anaerobic intestinal 
microorganisms, but can be negatively affected by external factors and these 
include antibiotic treatments [IAPICHINO et al., 2008] and chemotherapy 
treatment [VAN VLIET et al., 2009]. Antibiotics and also chemotherapeutic 
intervention are discussed to perturb the indigenous biota to allow consistent 
enteric infection by a variety of pathogens including Salmonella enterica, Vibrio 
cholerae, Escherichia coli, Enterococcus faecalis as well as Clostridium difficile, 
may resulting in severe gastrointestinal disturbances like Clostridium difficile-
associated diarrhoea (CDAD) [CROSWELL et al., 2009, SCHALK et al., 2009, 
VAN VLIET et al., 2009]. Clostridium difficile and the emergence in patients 
receiving chemotherapy will be discussed later. 
 
4.3 BACTERIAL COMMUNITIES 
The distal human intestine represents an anaerobic bioreactor programmed 
with an enormous population of bacteria, dominated by relatively few divisions 
that are highly diverse at the strain/subspecies level [BACKHED et al., 2005]. 
Members of nine bacterial phyla were found to inhabit the human 
gastrointestinal tract of which Firmicutes, Bacteroidetes and Actinobacteria are 
dominant. Only a limited number of individuals have yet been subjected to the 
analysis of intestinal microbial diversity and due to individual differences, it is 
still difficult to define a ‘normal and healthy’ composition of the microbiota 
[RAJILIC-STOJANOVIC et al., 2007]. However, diversity is generally thought to 
be desirable for ecosystem stability and resilience [BACKHED et al., 2005].  
 
The following part will focus on the Bacteroides, bifidobacteria and Clostridium 
cluster IV and XIVa group as well as on Clostridium difficile, which are subject 
of this work. 
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4.3.1 Bacteroides 
The bacteroides subgroup is one of the major populations within the gut 
community and is characterized as obligate anaerobic, gram-negative and non-
sporulating [OHKUMA et al., 2002]. These bacteria have significant effects on 
human health, most notably in carbohydrate fermentation and catabolism of 
polysaccharides. Some strains are important opportunistic pathogens, such as 
B. fragilis [LI et al., 2009]. Bacteroides species have been reported to show high 
variations between individuals, although Bacteroides thetaiotaomicron is found 
in all humans [ZWIELEHNER et al., 2009], is  very successful in digesting 
otherwise indigestible dietary polysaccharides [BACKHED et al., 2005] and 
some members of this group are fibrolytic and produce butyrate [LISZT et al., 
2009]. The impact of butyrate on intestinal health will be described in later. 
Additionally, the bacteroides group is discussed to be part of the ‘ageing 
microbiota’ [MARIAT et al., 2009] and seems to be related with obesity, showing 
that the microbiota of obese mice and humans include fewer bacteroidetes 
[DIBAISE et al., 2008]. 
 
4.3.2 Bifidobacteria 
Bifidobacteria are Gram positive bacteria belonging to the class Actinobacteria. 
Among the commensal bacteria that are resident in the mammalian GIT, 
Bifidobacteria represent one of the most numerous “probiotic” groups and are 
predicted to constitute less than 10%, depending on age and diet [TURRONI et 
al., 2008]. Stimulation of these bacteria has previously been described after 
prebiotic intervention with inulin and fructo-oligosaccharides [KOLIDA et al., 
2007]. Furthermore, they have been shown to be involved in the prevention of 
atopic disease [OUWEHAND, 2007], obesity and insulin resistance via 
enhanced barrier function of the gut epithelium [CANI et al., 2007]. 
 
4.3.3 Clostridium cluster IV 
The predominant intestinal clostridia belong mainly to cluster XIVa (Clostridium 
coccoides – Eubacterium rectale group) and IV (Clostridium leptum group). 
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Some members of these populations are saccharolytic and/or proteolytic 
species and are able to metabolize a wide variety of substrates. In the colon 
they are important in the fermentation and putrefaction of food-derived 
substances, resulting in various metabolites such as fatty acids and gases 
[MAUKONEN et al., 2006]. Therefore, members of Clostridium cluster IV are 
known to be involved in beneficial functions, including nutrient absorption and 
epithelial cell maturation and maintenance [WOODMANSEY, 2007]. 
 
4.3.4 Clostridium cluster XIVa 
As mentioned above, Clostridium cluster XIVa is one of two abundantly 
represented clusters of Firmicutes in the human colon [MAHOWALD et al., 
2009]. The Clostridium cluster XIVa group contains many butyrate-producing 
strains, including Roseburia and relatives that can degrade starch and inulin. 
Furthermore, important non-butyrate producing members of group XIVa are 
Ruminucoccus torques and R. gnavus, which are among the primary mucin-
degrading organisms [DETHLEFSEN et al., 2006]. Other functionally significant 
attributes that have been identified for clostridial cluster XIVa species include 
acetogenesis, utilization of aromatic compounds from the diet and metabolism 
of linoleic acid but the phylogenetic distribution of these attributes is not yet fully 
established [FLINT et al., 2007]. 
 
4.3.5 Clostridium difficile 
Clostridium difficile is a Gram-positive, spore forming anaerobic bacterium that 
can reside asymptomatically within the intestinal tract of humans [LAWLEY et 
al., 2009]. The use of broad-spectrum antibiotics disrupt the ecosystem of the 
normal colonic biota, and may predispose to dense colonization with C. difficile, 
and lead to C. difficile associated diseases (CDAD). Patients on antibiotics, 
hospitalized patients, those with malignancies, immunosuppressed patients and 
the elderly are all prone to develop CDAD [BALAMURUGAN et al., 2008]. This 
bacterium is thought to be the causative agent in up to 20% of antibiotic 
associated disease (AAD) patients. Most of the cases of AAD are thought to be 
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due to a disturbance of the intestinal microbiota by antibiotics, which are 
associated with loss of colonization resistance, changes in carbohydrate 
digestion and production of short-chain fatty acids, altered metabolism of bile 
acids and changes in both the mucosal and systemic immune system [KONING 
et al., 2008]. Clostridium difficile seems to be a severe complication of 
aggressive chemotherapy too [SCHALK et al., 2009]. In this context the 
incidence of Clostridium difficile was analyzed in patients receiving 
chemotherapy and will be subsequently explained in greater detail. 
 
4.4 MICROBIOTA CHANGES WITH AGE 
The intestinal microbiota is relatively stable throughout adult life and has been 
extensively studied; recent studies indicate that modifications and structural 
changes occur from infants to elderly individuals [MARIAT et al., 2009].  
 
Diet is an important determinant of bowel function and age-related changes in 
the amounts and types of food consumed caused by a decline in taste and 
smell, masticatory dysfunction and swallowing difficulties may be important 
factors contributing to alterations in the gut ecology in old age [BARTOSCH et 
al., 2004]. Additionally, immunological changes occur in the body with 
advancing age. Other age related shifts, such as decreased gastric acid 
secretion and increased mucosal permeability in the gut, have been linked to 
increases in circulating antibodies to bacteria in the microbiota in elderly 
subjects [HOPKINS et al., 2001]. Therefore, the inflammatory status of old age 
can be nutured from intestinal environment [GUIGOZ et al., 2008].  All this 
together enables new bacterial populations to exploit novel ecological niches, 
thereby changing the composition and activities of the microbiota [HOPKINS et 
al., 2001]. 
 
With ageing, a decline in counts of Bacteroides with increased age 
[WOODMANSEY, 2007] was reported and the species diversity within the 
genus Bacteroides is reportedly reduced in elderly compared with the healthy 
adults [ZWIELEHNER et al., 2009]. As mentioned above, Bacteroides species 
9 
 
 
 
are nutritionally versatile and changes within this bacterial community could 
have considerable consequences for the elderly host. In conjunction with the 
shifts observed in the genus Bacteroides, the decline in beneficial bifidobacteria 
is one of the most marked changes in the elderly gut [WOODMANSEY, 2007]. 
The majority of studies in the literature report a decrease of beneficial 
Lactobacilli [ZWIELEHNER et al., 2009] and an increase in Clostridia in elderly 
subjects, particularly following antibiotic therapy [WOODMANSEY, 2007, 
ZWIELEHNER et al., 2009]. 
 
These changes of the aged may favour gastrointestinal infections that are 
frequent in the elderly, including Clostridium difficile-associated diarrhoea, what 
has become a major problem in the elderly hospitalized and nonhospitalized 
patient [HEBUTERNE, 2003]. 
 
Figure 1 shows an overview of the key changes to intestinal microbiota 
observed in elderly populations [WOODMANSEY, 2007]. 
 
 
Figure 1 Changes of the GI microbiota in elderly populations 
(ABE = antibiotic-treated elderly) 
 
10 
 
 
 
4.5 SHORT CHAIN FATTY ACIDS, BUTYRATE 
Short-chain fatty acids (SCFAs), primarily acetate, propionate and butyrate, are 
organic acids produced within the intestinal lumen by bacterial fermentation or 
mainly undigested dietary carbohydrates.  
 
An important SCFA produced is butyrate that besides being an energy source 
for the epithelial cells also influences a wide array of cellular functions affecting 
colonic health. As such, butyrate may have an anticarcinogenic and anti-
inflammatory potential and affect the intestinal barrier and play a role in satiety 
and oxidative stress [HAMER et al., 2008, HAMER et al., 2009]. Frequently 
described are the effect on gene expression because of the inhibition of histone 
deacetylase and suppression of NF-κB activation [HAMER et al., 2008]. Cell 
culture studies have indicated that the presence of butyrate at physiological 
concentrations enhances the growth of normal enterocytes and inhibits that of 
malignant ones [MCORIST et al., 2008]. In contrast, a few animal and in vitro 
studies demonstrate negative effects at higher butyrate concentrations on 
permeability and visceral sensitivity of the large intestine [HAMER et al., 2008]. 
Thus, the relative and physiologic production rates of these SCFA provide a 
potentially important link between diet and colonic health and disease 
[BARCENILLA et al., 2000]. 
 
The human colon harbours butyrate-producing species of several genera such 
as Clostridium, Eubacterium and Fusobacterium [ZWIELEHNER et al., 2009]. 
Barcenilla et al. (2000) showed that 80% of butyrate-producing isolates of 
human faecal origin belonged to the clostridial phylogenetic cluster XIVa 
[MAUKONEN et al., 2006]. 
 
A screen of 38 butyrate-producing bacteria from the human colon revealed that 
the Butyryl-CoA CoA-transferase pathway is the predominant route of butyrate 
formation in bacteria adapted to live within gut ecosystems, as they use the 
Butyryl-CoA CoA-transferase gene for the last step of butyrate formation 
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[LOUIS et al., 2007]. Therefore, abundance of this gene was analyzed by Hippe 
et al. in faecal samples of elderly, young omnivores and vegetarians. 
 
In order to link this section with the ‘ageing microbiota’ and the ‘microbiota in 
times of immunosuppression (chemotherapy and antibiotics)’, studies of 
bacterial fermentation products in their faeces have shown a decrease in SCFA 
production in elderly people, associated with a decrease in the number of 
Bacteroides and bifidobacteria. A recent study reveals a close relationship 
between the decrease in butyrate-producing bacteria and antibiotic-associated 
diarrhoea, suggesting that a decline of SCFAs may also play a role [ROY et al., 
2006]. 
 
4.6 MICROBIOTA IN IMMUNODEFICIENCY, E. G.: CHEMOTHERAPY, 
ANTIMICROBIAL THERAPY 
Changes of the microbiota are also observed in pathological conditions such as 
infections, antibiotic therapy, anti-acid therapy and immune suppression 
[SCHIFFRIN et al., 2002].  
 
Infections and inflammatory complications remain among the most-encountered 
serious complications of chemotherapy treatment among patients with cancer, 
accounting for morbidity and mortality, despite the use of prophylactic antibiotics 
[VAN VLIET et al., 2009]. Chemotherapy damages the rapidly generated 
mucosal cells of the gastrointestinal tract, causing diarrhoea or constipation and 
creating a source for bacterial invasion [GIBSON et al., 2006, NYHLEN et al., 
2002]. For this reason mucositis is a major oncological problem, caused by the 
cytotoxic effects of cancer chemotherapy and radiotherapy. Approximately 40% 
of patients receiving standard dose chemotherapy and 100% of patients 
receiving high dose chemotherapy and stem cell or bone marrow 
transplantation exhibit abdominal pain, ulceration, bloating, vomiting and 
diarrhoea typically associated with mucositis, especially large intestine 
mucositis [STRINGER et al., 2007, STRINGER et al., 2009]. In addition, 
chemotherapy is reported to destroy the brush border enzymes, which are 
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responsible for the digestion of both carbohydrates and proteins, possibly 
affecting the intestinal butyrate production. Bacterial overgrowth has also been 
reported to be a significant cause of clinical diarrhoea; hence, the damage to 
crypts leads to the risk of opportunistic infections [GIBSON et al., 2006].  
 
Accompanying antibiotic treatment carries both benefit and risk [CROSWELL et 
al., 2009]. Antibiotic therapy may influence the human intestinal microbiota, 
resulting in induction of antimicrobial resistance, overgrowth of pathogens like 
Clostridium difficile and reduction in colonization resistance. Several 
antineoplastic drugs are known to have an antimicrobial effect [NYHLEN et al., 
2002]. 
 
Previous studies have investigated the effect of chemotherapeutics and 
antibiotics on intestinal microbiota, but still little is known about the direct effects 
of cytostatic drugs on the intestinal microbiota of humans [NYHLEN et al., 
2002]. For this reason, we analyzed changes of predominant bacteria in human 
faeces as a response to chemotherapeutic and antibiotic intervention. 
 
4.7 THE MICROBIOTA AS THERAPEUTIC TARGET  
Recent increased interest in an influence of intestinal microbiota on human 
health and disease resulted in attempts of improving optimally its composition 
by using probiotics, prebiotics and combinations of both, synbiotics 
[TLASKALOVA-HOGENOVA et al., 2004]. 
 
Probiotics are defined as “live microorganisms which when administered in 
adequate amounts confer a health benefit to the host” [NEISH, 2009]. In 
addition to bacterial strains Lactobacillus and Bifidobacter, also some non-
pathogenic strains of E. coli proved suitable for this purpose [TLASKALOVA-
HOGENOVA et al., 2004]. Clinical evidence indicates that probiotics are 
effective in the treatment or prevention of acute viral gastroenteritis, 
postantibiotic-associated diarrhea, certain pediatric allergic disorders, 
necrotizing enterocolitis and inflammatory bowel disease (IBD) [NEISH, 2009]. 
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“A prebiotic is a non-digestible food ingredient that beneficially affects the host 
by selectively stimulating the growth and/or activity of one of a limited number of 
bacteria in the colon, and thus improves host health” [MACFARLANE et al., 
2006]. These complex carbohydrates (inulin, oligofructose) can increase 
concentrations of SCFAs, including butyrate and indirectly modify immune 
functions [NEISH, 2009]. 
 
Finally, although it might be challenging to select save probiotics that would 
improve the ecological health of the microbiota, it might be more immediately 
practical to provide supplementary bacteria to restore a deficiency following 
treatment with antibiotics and maybe chemotherapy too. This would prevent the 
expansion of opportunistic pathogens and stimulate cytoprotective responses 
[NEISH, 2009]. 
 
5 MATERIAL AND METHODS 
 
This chapter will focus on study design, materials and methods used for the 
work “Changes in human faecal microbiota due to chemotherapy analyzed by 
TaqMan-PCR and PCR-DGGE fingerprinting” by Lassl et al.. The same 
molecular techniques were used in the works of Zwielehner et al. and Hippe et 
al., excluding the HPLC-RI method and the use of degenerate primer sets. For 
detailed information, these methods are described in the attached manuscript 
by Hippe et al.. 
 
5.1 MICROBIOTA DURING CHEMOTHERPY AND ANTIBIOTIC 
TREATMENT 
Figure 2 shows a schematic overview of the study design and the used 
methods for assessing the bacterial composition of patients receiving 
chemotherapy. Afterwards every single step will be described in more detail. 
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Figure 2 Overview of study design and used methods for this thesis 
 
5.1.1 Study participants and study design 
Eleven subjects receiving chemotherapy ± antimicrobial therapy (aged 55 ± 14 
years, BMI 28 ± 7) from the Sozialmedizinisches Zentrum Ost in Vienna and 
nine healthy individuals (aged 55 ± 21 years, BMI 24 ± 5) joined this study. 
Faecal samples of each ambulant oncology patient were collected at four time 
points before or after the onset of treatment within two weeks. The term “out of 
chemotherapy” is used in the following sections for samples that are currently 
not unter chemotherapeutical intervention. Two out of nine patients had never 
received any chemotherapy before, while the others had a longer history of 
chemotherapy. Stool samples of healthy individuals were collected once.  
All study participants were interviewed assessing: age; gender; body length; 
weight; health status (chronic and acute diseases); life-style aspects such as 
cigarette and alcohol consumption as well as physical activity.  Dietary habits 
were assessed using a food frequency questionnaire. Exclusion criteria for 
healthy controls were (a) antimicrobial medication (b) chemotherapeutic 
treatment and (c) pre- and probiotics for at least three months period before the 
collection of faecal samples. One subject receiving chemotherapy additionally 
suffered from rheumatism while another subject suffered from diabetes mellitus 
type II, hypertension and obesity. Study populations were gender balanced, with 
55% females in both, oncology patients and healthy controls.  
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Furthermore, patients’ medical records reported chemotherapeutic and 
antimicrobial treatment. All subjects gave written informed consent. The study 
was approved by the ethics committee of Vienna. 
 
5.1.2 Extraction of bacterial DNA 
After collection, stool samples were brought to the laboratory and immediately 
stored at -70°C. A 200 mg aliquot of each sample was treated twice for 45 s in a 
bead-beater (Mini-Beadbeater-8). Thereafter DNA was extracted using the 
QIAamp® DNA Stool Mini Kit (QIA-GEN) following the manufacturer’s protocol. 
Finally we stored the DNA at -20°C until the analysis was conducted. 
 
5.1.3 Type strains 
Type strains, knowing to be a part of the human gastrointestinal microbiota and 
cloned sequences were used to design a DGGE standard lane marker. Type 
strains Bacteroides thetaiotaomicron DSM 2079T, Enterococcus faecium DSM 
20477 T, Lactobaccilus reuteri ATCC 55730 T, Bifidobacterium longum ssp. 
longum DSM 20097 T, Escherichia coli IMBH 252/07 and clones CL16 and 
CC34 were used creating a comparable standard lane marker for DGGE gels 
analyzing bacteria. 
 
5.1.4 Cloning 
To create a standard lane marker for DGGE analysis and identifying dominant 
members of the Clostridium cluster XIVa we constructed a clone library from 
faecal samples. Therefore PCR products amplified with primers 195-F [MEIER 
et al., 1999] and Ccocc-R [MATSUKI et al., 2004] were inserted into a p-GEM 
Easy Vector (Promega) following the instructions of the manufacturer. We 
picked fourty clones, amplified with primer pair T7/Sp6 (Promega) and checked 
fragment length on 2% agarose gel before clone inserts were sequenced by 
‘DNA confidence’ (Vienna). Finally, nucleotide sequences were corrected for 
primer and vector sequences in CodonCodeAligner (www.codoncode.com) and 
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taxonomically identified using the ribosomal database project 
(http://rdp.cme.msu.edu/). The clone library used for creating a standard lane 
marker for DGGE analysis of Clostridium cluster IV has previously been 
described [ZWIELEHNER et al., 2009]. 
 
5.1.5 Polymerase chain reaction (PCR) 
PCR was carried out amplifying 16S rRNA gene sequences from bacteria in 
faecal samples, type strains and DGGE analysis as well as for creation of the 
clone library using group-specific and kingdom-specific primers (Table 1). The 
PCR reaction mixture consisted of ready-to-use mastermix (Promega) with1.5 
mMMgCl2, 500nmol/L of both primers and 2 µl of template DNA. When 
amplifying faecal samples, bovine serum albumin (Fermentas) was added to a 
final concentration of 400µg/ml. We used a Robocycler (Stratagene) for all 
amplifications. 
 
5.1.6 Diversity measurement – PCR-DGGE 
DGGE was performed as described by Muyzer et al. [MUYZER et al., 1993]. 
Primer pairs and annealing temperatures to analyze the diversity of (a) bacteria, 
(b) Clostridium cluster IV and (c) Clostridium cluster XIVa are described in 
Table 1.  
PCR products were separated by polyacrylamid gels with a denaturing gradient 
of 30-60% for predominant bacteria, 30-50% for Clostridium cluster IV and 35-
50% for Clostridium cluster XIVa using a gradientmixer (Hoefer SG 30) and a 
peristaltic pump. Electrophoresis was performed for 9 h at 130 V at 60°C 
(predominant bacteria), 5 h at 200V at 60°C (Clostridium cluster IV) and 7 h at 
200 V at 60°C (Clostridium cluster XIVa). We created a standard lane marker 
for each DGGE analysis assay to ensure reliable gel-to-gel comparison. These 
standard lane markers (described above) were loaded in triplicate on each gel 
to adjust gradient-variations within one gel. 
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Target organism Primer pairs Sequence (5' - 3') 
Ann. temp 
(°C) 
Reference 
Bacteria 
341F-GC CCT ACG GGA GGC AGC AG 55 
[MUYZER et 
al., 1993] 
 
518-R ATT ACC GCG GCT GCT GG 55 
[NEEFS et 
al., 1991] 
Clostridium cluster IV sg-Clept-F-
GC 
GCA CAA GCA GTG GAG T 55 
[MATSUKI et 
al., 2004] 
 sg-Clept-R CTT CCT CCG TTT TGT CAA 55  
Clostridium cluster XIVa 
Ccocc-F-GC AAA TGA CGG TAC CTG ACT AA 50 
[MATSUKI et 
al., 2004] 
 
Ccocc-R 
CTT TGA GTT TCA TTC TTG CGA A 
 
50  
 
Table 1 Primers for PCR-DGGE fingerprinting of 16S rRNA coding regions 
 
5.1.7 Quantitative measurement – TaqMan-qPCR 
The abundance of bacteria and bacterial subgroups was measured by 16S 
rRNA gene-targeting with TaqMan detection. Optimal annealing temperature of 
the PCR primer pairs and expected product sizes (Table 2) were ascertained 
using a Robocycler (Stratagene), before the TaqMan-assay was performed in a 
Rotorgene 3000 (Corbett Life Science). We analyzed each sample in duplicate. 
Briefly, amplification reactions were carried out in a total volume of 10µl 
consisting of 5µl Taq-Man SensiMix DNA Kit (Quantance), 1µl of each primer 
and Taq-Man-probe (concentrations in a final volume of 10µl see table 2) and 
2µl of bacterial DNA. Amplification programs included an initial denaturation at 
95°C for 10 min followed by 40 cycles of denaturation step at 95 °C for 30 s, 
primer annealing at 55 °C (bacteria, Clostridium cluster IV), 56 °C (Clostridium 
cluster XIVa), 58 °C (Clostridium difficile) or 60 °C (bacteroides, Bifidobacteria) 
for 30 s and extension at 72 °C for 50 s.  
We used tenfold serial DNA dilutions of type strains Bacteroides 
thetaiotaomicronT, Bifidobacterium longum ssp. longumT and Clostridium 
difficile as well as the clones CL16 and CC34 and one faecal sample to 
construct standard curves for comparison of PCR reaction efficiencies among 
different experiments.  
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We quantified DNA of Bacteroides thetaiotaomicronT, Bifidobacterium longum 
ssp. longumT and Clostridium difficile, using the nanodrop method and 
calculated DNA copies/µl through mean G+C content of each strain. 
Quantification of clones CL16 (Clostridium leptum 16) and CC34 (Clostridium 
coccoides 34) was done determining the numbers of CFU (colony forming 
units). Relative percentages of bacterial subgroups were calculated in relation 
to total rRNA gene copies amplified with primer pair BAC-338-F and BAC-805-R 
[YU et al., 2005].  
Sensitivity of PCR reactions was determined with stepwise dilutions of standard 
curve DNA. The specifity was confirmed using non-target DNA. All samples 
were measured in double approach and the average was used for calculation.  
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Target organism Primer and probe Sequence (5' - 3') Size (bp) 
Conc. 
(nM) 
Reference 
Bacteria BAC-338-F ACT CCT ACG GGA GGC AG 468 1000  
 BAC-805-R GAC TAC CAG GGT ATC TAA TCC  1000  
 
BAC-516-P 
(6-FAM)-TGC CAG CAG CCG CGG TAA 
TAC-(BHQ-1) 
 200 
[YU et al., 
2005] 
Bacteroides AllBac296f GAG AGG AAG GTC CCC CAC 106 300  
 AllBac412r CGC TAC TTG GCT GGT TCA G  300  
 
AllBac375Bhqr 
(6-FAM)-CCA TTG ACC AAT ATT CCT 
CAC TGC TGC CT-(BHQ-1) 
 100 
[LAYTON et 
al., 2006] 
Bifidobacteria Fwd primer GCG TGC TTA ACA CAT GCA AGT C 125 300  
 Rev primer CAC CCG TTT CCA GGA GCT ATT  300  
 
Probe 
(6-FAM)-TCA CGC ATT ACT CAC CCG 
TTC GCC-(BHQ-1) 
 150 
[PENDERS 
et al., 2005] 
Clostridium cluster IV 
sg-Clept-F GCA CAA GCA GTG GAG T 239 400 
[MATSUKI et 
al., 2004] 
 sg-Clept-R CTT CCT CCG TTT TGT CAA  400  
 
Clept-Pa (FAM)-AGG GTT GCG CTC GTT-(BHQ-1) 538 200 
[ZWIELEHN
ER et al., 
2009] 
Clostridium cluster XIVa 
195-F 
GCA GTG GGG AAT ATT GCA 
 
 500 
[MEIER et 
al., 1999]  
 
Ccocc-R 
CTT TGA GTT TCA TTC TTG CGA A 
 
 500 
[MATSUKI et 
al., 2004] 
 
Ccocc-P 
(6-FAM)-AAA TGA CGG TAC CTG ACT 
AA-(BHQ-1) 
 150  
Clostridium difficile 
Cdiff-F TTG AGC GAT TTA CTT CGG TAA AGA 151 1000 
[PENDERS 
et al., 2005] 
 
Cdiff-R 
TGT ACT GGC TCA CCT TTG ATA TTC 
A 
 1000  
 
Cdiff-P 
(6-FAM)-CCA CGC GTT ACT CAC CCG 
TCC G-(BHQ-1) 
 200  
 
Table 2 Primers and TaqMan-probes targeting 16S rRNA coding regions of 
faecal bacteria for absolute and relative quantification used in this study 
 
5.1.8 Statistical analysis 
Statistical evaluation of differences between groups (chemotherapy and control) 
and changes within the chemotherapy group (all time points during 
chemotherapy, time points after chemotherapy or out of chemotherapy) was 
carried out using the OriginPro version 8 (OriginLab, Northampton, MA). For 
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two group comparisons of independent ordinal and interval values the two-
sample-T-test and the non-parametric Mann-Whitney-U-test were used. For the 
analysis of related data the paired-sample-T-test or the non paremetric 
Wilcoxon-signed-ranked-test were used. P values below 0.05 were considered 
statistically significant. 
PCR-DGGE bands were analyzed in GelComparII (www.applied-maths.com) 
and compared with principal component analysis (PCA) using the default 
settings in ‘R-software environment for statistical computing’ (www.r-project.org) 
until 100% variance was explained. Clustering was performed applying Dice 
coefficient and UPMGA dendrograms. Shannon and Simpson diversity indices 
were calculated on quantitative band information with the default settings 
implemented in the ‘vegan’ package in ‘R’. Shannon index is defined as H = -∑ 
pi ln pi, where pi is the proportional abundance of species i. For Simpson index, 
given as 1 - D, this is 1 - ∑(( pi)^2), pi is the relative frequency of the i-th species 
[ZWIELEHNER et al., 2009]. In short, the higher the Simpson (0-1) and 
Shannon indices are, the higher the diversity. 
 
5.2 AGEING RELATED SHIFTS OF THE MICROBIOTA 
The aim of the study by Zwielehner et al. was to investigate ageing-related 
shifts in diversity and composition of bacteria, Bacteroides, bifidobacteria and 
Clostridium cluster IV by comparing industrialized elderly (n=17, 78-94 years) 
and young individuals (n=17, 18-31 years). Therefore, qPCR with TaqMan-
detection and PCR-DGGE fingerprinting methods were used.  
 
5.3 BUTYRATE 
The work by Hippe et al. aimed to detect differences in butyrate production by 
Buryryl-CoA CoA-transferase gene analysis in faecal samples and measuring 
butyrate concentration via HPLC-RI. The study population consisted of 
industrialized elderly (n=17, age=86±8), young omnivores (n=17, age=24±2.5) 
and young vegetarians (n=16, age=26±5).  
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6 RESULTS 
 
Results and data of all three described parts of this thesis will be presented in 
the following chapter. Whereas the aging- and butyrate-results are presented in 
short, this chapter is principally concerned with the chemotherapy-results, as 
my research focused on this issue. 
 
6.1 MICROBIOTA DURING CHEMOTHERAPY AND ANTIBIOTIC 
TREATMENT 
6.1.1 Dietary aspects 
The participants` dietary habits were assessed using a food frequency 
questionnaire. All study participants (patients and controls) were omnivores and 
showed similar consumption patterns of liquids, alcohol, fruits, vegetables, 
grains and milk products. Healthy controls stated more frequent consumption of 
fruits, whole grain products and alcohol several times a week compared to 
patients receiving chemotherapy (not significant).  
6.1.2 qPCR quantification and statistical interpretation 
Table 3 shows result from the real time PCR quantification in absolute numbers 
of bacteria and bacterial subgroups, including mean values and standard 
deviations for oncology patients and healthy controls.  
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ON´s Allbac.absolute Bac.absolute Bif.absolute Clept.ablolute Ccocc.absolute Cdiff.absolute Unidentified.absolute
ON001/1 1.798.805,94           686.436,18        22.965,45        431.283,01          179.653,46        478.467,84                     
ON001/2 372.479,33              214.081,92        4.558,69          66.859,19            17.518,96          69.460,57                       
ON001/3 1.183.463,77           453.079,56        30.777,49        349.670,05          81.729,38          268.207,30                     
ON001/4 4.900.917,36           1.757.221,14     69.416,26        894.221,86          492.005,88        1.688.052,22                  
ON002/1 20.212.193,78         5.354.904,16     25,84               1.727.067,70       8.456.716,97     4.673.479,10                  
ON002/2 23.903.696,36         4.005.111,16     366,48             1.926.246,84       6.273.075,75     11.698.896,13                
ON002/3 3.129.907,77           1.537.813,68     65,15               899.451,34          202.334,40        490.243,20                     
ON002/4 42.134.076,47         8.601.362,67     266,24             6.391.142,51       11.186.629,09   15.954.675,96                
ON003/1 5.252.430,48           330.458,04        303.812,95      1.584.639,87       703.331,31        2.330.188,31                  
ON003/2 32.539.656,72         7.049.121,86     1.322.331,64   11.554.656,05     10.912.078,21   1.701.468,96                  
ON003/3 8.776.038,82           1.914.216,02     68.520,97        1.613.986,64       3.585.565,52     1.593.749,67                  
ON003/4 34.133.421,73         5.633.416,81     368.271,38      6.935.425,53       17.973.732,55   3.222.575,46                  
ON004/1 10.176.085,75         3.675.199,65     123.237,25      2.790.373,95       1.828.490,92     1.758.783,98                  
ON004/2 2.041.417,98           124.427,95        6.748,31          1.044.114,49       456.546,61        409.580,63                     
ON004/3 9.397.403,84           2.436.596,74     150.717,25      2.484.676,03       1.113.862,60     3.211.551,22                  
ON004/4 17.611.326,10         3.143.896,40     388.478,41      5.200.829,47       1.762.498,85     7.115.622,98                  
ON005/1 58.606.024,90         7.574.676,76     1.485.218,67   8.089.718,24       10.498.104,44   30.958.306,80                
ON005/2 77.914.671,15         9.930.958,08     4.295.028,01   24.053.291,85     25.121.947,29   14.513.445,92                
ON005/3 47.867.203,61         10.669.686,99   2.232.338,50   8.288.562,23       21.327.802,26   5.348.813,62                  
ON005/4 45.546.066,19         8.990.544,45     1.150.309,59   11.197.726,83     23.100.668,54   1.106.816,77                  
ON006/1 4.254.777,75           1.117.961,90     150.748,62      648.065,08          1.921.015,97     416.986,18                     
ON006/2 19.663.552,55         4.064.824,71     143.528,56      1.769.516,54       4.984.825,07     8.700.857,66                  
ON006/3 5.817.626,36           1.692.997,14     126.902,02      1.911.000,59       1.832.499,43     254.227,18                     
ON006/4 11.491.330,22         2.619.686,08     354.166,89      1.450.849,53       3.690.397,55     3.376.230,17                  
ON007/1 32.882.071,40         13.715.080,97   897,46             3.410.583,24       7.731.920,78     8.023.588,95                  
ON007/2 14.010.666,45         2.027.428,84     1.032,00          2.671.080,63       1.991.983,19     7.319.141,79                  
ON007/3 31.475.072,44         16.519.292,63   823,50             1.586.561,05       13.562,81          13.354.832,44                
ON007/4 210.972,37              82.379,99          34,45               55.314,07            9.572,75            63.671,12                       
ON008/1 20.526.835,88         5.611.144,84     718,75             1.247.117,30       7.680.688,02     5.987.166,97                  
ON008/2 44.425.634,50         16.318.239,73   895,78             3.476.321,68       15.493.685,21   9.136.492,11                  
ON008/3 25.709.141,44         11.964.895,51   718,60             2.268.109,88       5.119.868,83     6.355.548,62                  
ON008/4 4.789.406,38           1.833.583,83     50,22               255.512,39          404.272,01        2.295.987,93                  
ON009/1 60.928.403,72         19.783.140,36   349.975,84      6.483.641,99       5.835.644,77     6.882,51           28.469.118,25                
ON009/2 79.557.247,54         24.331.906,09   426.303,13      7.125.594,64       6.230.655,43     3.410,13           41.439.378,12                
ON009/3 18.692.507,80         7.732.250,88     2.051,63          1.534.255,90       6.614.636,98     228.486,37       2.580.826,05                  
ON009/4 22.422.312,29         7.987.608,92     13.249,55        1.508.579,53       2.774.425,14     90.328,31         10.048.120,85                
ON010/1 13.477.917,70         2.837.015,05     73,34               1.122.511,68       1.498.517,07     8.019.800,57                  
ON010/2 18.520.677,78         2.213.914,71     15,13               830.143,08          993.439,98        14.483.164,88                
ON010/3 52.591.368,06         5.899.979,48     3.869,15          2.670.649,71       4.623.410,70     39.393.459,02                
ON010/4 21.962.667,14         5.147.834,94     1.465,47          1.149.697,73       2.797.644,59     12.866.024,42                
ON011/1 44.187.524,40         6.037.882,96     441.875,24      2.509.998,68       2.374.357,37     32.823.410,14                
ON011/2 9.505.774,72           865.600,46        95.057,75        1.175.348,89       2.030.535,80     5.339.231,83                  
ON011/3 4.652.268,06           1.640.708,80     0,05                 180.029,67          397.823,15        181.438,45       2.252.267,92                  
ON011/4 30.489.412,48         5.277.219,74     0,29                 32.637,34            292.051,98        243.915,30       24.643.587,83                
mean value 23.630.510,40         5.713.767,93     321.316,09      3.286.296,92       5.286.630,17     125.743,51       9.005.352,45                  
standard deviation 20.746.842,40         5.581.373,91     766.855,30      4.329.980,87       6.472.251,56     107.675,65       10.688.197,15                
C´s Allbac.absolute Bac.absolute Bif.absolute Clept.ablolute Ccocc.absolute Cdiff.absolute Unidentified.absolute
C001 67.127.580,45         21.630.083,97   1.104.596,65   3.016.391,93       22.372.916,47   19.003.591,43                
C002 126.948.085,08       19.212.984,02   2.462.247,54   9.444.500,94       68.718.443,26   27.109.909,32                
C003 65.278.056,00         25.196.457,64   472.238,95      1.610.808,79       14.988.708,20   23.009.842,41                
C004 22.910.236,96         3.611.549,33     121.147,51      750.523,91          6.857.928,70     11.569.087,50                
C005 47.074.467,77         18.138.079,80   353.519,38      1.308.964,14       12.538.810,79   14.735.093,66                
C006 80.856.946,54         4.609.927,63     105.023,05      12.371.776,73     54.236.684,90   9.533.534,22                  
C007 58.912.801,05         10.278.138,84   527.253,76      8.869.928,30       37.824.150,42   1.413.329,73                  
C008 137.945.616,44       15.770.084,32   510.575,47      34.278.520,13     5.002.288,46     82.384.148,07                
C009 30.738.626,46         10.320.149,60   576.296,72      2.839.348,81       3.367.532,31     1.807,64           13.633.491,38                
mean value 70.865.824,08         15.612.467,88   722.274,14      11.778.939,46     40.454.085,96   1.807,64           22.488.003,08                
standard deviation 39.383.963,12         6.599.890,79     703.559,31      15.979.257,31     60.636.038,36   23.693.396,92                 
Table 3 Absolute numbers of bacteria and bacterial subgroups 
 
Figure 3 illustrates the impact of medical treatment (chemotherapy and 
antibiotics) on human faecal microbiota. Absolute numbers of Bacteroides 
(Bac), bifidobacteria (Bif), Clostridium cluster IV (Clept) and XIVa (Ccocc), 
Clostridium difficile (Cdiff) and unidentified bacteria analyzed by TaqMan-qPCR 
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are shown (Figure 3). The microbiota composition of every patient receiving 
chemotherapy (ON) and control individual (C) is shown in detail. The absolute 
numbers are related to 2µl of faeces extract (x 1.000.000). The abbreviation 
‘ChT’ stands for Chemotherapy, ‘Ab’ for Antibiotics, ‘F’ stands for fever and ‘T’ 
for blood stem cell transplantation. The pattern over the bar chart indicates 
sampling points during chemotherapy (yellow fields), out of chemotherapy, 
during antibiotic intervention (gray fields), during fever and when blood stem cell 
transplantation occurred. Subject ON001 received chemotherapy before 
sampling. 
 
 
Figure 3 Microbiota composition of the study population in absolute numbers 
 
Patients receiving chemotherapy harboured only 25 ± 22% of the absolute 
bacterial load in their faeces compared to healthy individuals. This decrease 
affected Bacteroides, bifidobacteria, Clostridium cluster IV and XIVa. Despite 
high inter- and intraindividual variations, the differences in absolute numbers of 
bacteria (p = 0.02), Bacteroides (p=0.01), bifidobacteria (p=0.001) and 
Clostridium cluster XIVa (p=0.001) were statistically significant. 
Figure 3 shows that time points after chemotherapeutical intervention often 
show a decline of all bacterial subgroups, followed by a rebound of bacterial 
abundance. Subject ON007 shows a sharp decline of bacteria and bacterial 
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subgroups at time point 4 following medication due to blood stem cell 
transplantation. 
 
In contrast to absolute numbers, Figure 4 and Table 4 show the quantification 
as percentage of total bacterial DNA. The mean proportion of Bacteroides in 
stool samples was 27 ± 12% in chemotherapy patients and 23 ± 12% in healthy 
individuals. The mean percentage of bifidobacteria in patients was 1.17 ± 1% 
and 1% ± 0.7% in controls. Patients harboured 16 ± 11% of Clostridium cluster 
IV and 20 ± 14% of Clostridium cluster XIVa, while controls harboured 10 ± 7% 
and 34 ± 22% of clostridial clusters IV and XIVa. The red circles in figure 4 
highlight the emergence of Clostridium difficile.  
 
 
Figure 4 Percentage of bacterial subgroups in relation to analyzed bacteria 
 
18% of oncology patients harboured Clostridium difficile. Patient ON009 
harboured C. difficile at four time points investigated with a mean proportion of 
0.4 ± 0.7 %, showing the highest level (1.22%) at sampling point 3 (highlighted 
in Figure 4). C. difficile emerged at time point 3 in patient ON011 (3.90% of all 
analyzed bacteria, highlighted in Figure 4). However, one control individual 
(C009) harboured C. difficile as well. 
25 
 
 
 
ON´s Bac% Bif% Clept% Ccocc% Cdiff% Unidentified%
ON001/1 38,16                       1,28                   23,98               9,99                     26,60                    
ON001/2 57,47                       1,22                   17,95               4,70                     18,65                    
ON001/3 38,28                       2,60                   29,55               6,91                     22,66                    
ON001/4 35,85                       1,42                   18,25               10,04                   34,44                    
ON002/1 26,49                       0,00                   8,54                 41,84                   23,12                    
ON002/2 16,76                       0,00                   8,06                 26,24                   48,94                    
ON002/3 49,13                       0,00                   28,74               6,46                     15,66                    
ON002/4 20,41                       0,00                   15,17               26,55                   37,87                    
ON003/1 6,29                         5,78                   30,17               13,39                   44,36                    
ON003/2 21,66                       4,06                   35,51               33,53                   5,23                      
ON003/3 21,81                       0,78                   18,39               40,86                   18,16                    
ON003/4 16,50                       1,08                   20,32               52,66                   9,44                      
ON004/1 36,12                       1,21                   27,42               17,97                   17,28                    
ON004/2 6,10                         0,33                   51,15               22,36                   20,06                    
ON004/3 25,93                       1,60                   26,44               11,85                   34,17                    
ON004/4 17,85                       2,21                   29,53               10,01                   40,40                    
ON005/1 12,92                       2,53                   13,80               17,91                   52,82                    
ON005/2 12,75                       5,51                   30,87               32,24                   18,63                    
ON005/3 22,29                       4,66                   17,32               44,56                   11,17                    
ON005/4 19,74                       2,53                   24,59               50,72                   2,43                      
ON006/1 26,28                       3,54                   15,23               45,15                   9,80                      
ON006/2 20,67                       0,73                   9,00                 25,35                   44,25                    
ON006/3 29,10                       2,18                   32,85               31,50                   4,37                      
ON006/4 22,80                       3,08                   12,63               32,11                   29,38                    
ON007/1 41,71                       0,00                   10,37               23,51                   24,40                    
ON007/2 14,47                       0,01                   19,06               14,22                   52,24                    
ON007/3 52,48                       0,00                   5,04                 0,04                     42,43                    
ON007/4 39,05                       0,02                   26,22               4,54                     30,18                    
ON008/1 27,34                       0,00                   6,08                 37,42                   29,17                    
ON008/2 36,73                       0,00                   7,83                 34,88                   20,57                    
ON008/3 46,54                       0,00                   8,82                 19,91                   24,72                    
ON008/4 38,28                       0,00                   5,33                 8,44                     47,94                    
ON009/1 32,47                       0,57                   10,64               9,58                     0,01                   46,73                    
ON009/2 30,58                       0,54                   8,96                 7,83                     0,00                   52,09                    
ON009/3 41,37                       0,01                   8,21                 35,39                   1,22                   13,81                    
ON009/4 35,62                       0,06                   6,73                 12,37                   0,40                   44,81                    
ON010/1 21,05                       0,00                   8,33                 11,12                   59,50                    
ON010/2 11,95                       0,00                   4,48                 5,36                     78,20                    
ON010/3 11,22                       0,01                   5,08                 8,79                     74,90                    
ON010/4 23,44                       0,01                   5,23                 12,74                   58,58                    
ON011/1 13,66                       1,00                   5,68                 5,37                     74,28                    
ON011/2 9,11                         1,00                   12,36               21,36                   56,17                    
ON011/3 35,27                       0,00                   3,87                 8,55                     3,90                   48,41                    
ON011/4 17,31                       0,00                   0,11                 0,96                     0,80                   80,83                    
mean value 26,84                       1,17                   16,22               20,39                   1,06                   35,22                    
standard deviation 12,68                       1,58                   11,01               14,43                   1,47                   20,72                    
C´s Bac% Bif% Clept% Ccocc% Cdiff% Unidentified%
C001 32,22                       1,65                   4,49                 33,33                   28,31                    
C002 15,13                       1,94                   7,44                 54,13                   21,36                    
C003 38,60                       0,72                   2,47                 22,96                   35,25                    
C004 15,76                       0,53                   3,28                 29,93                   50,50                    
C005 38,53                       0,75                   2,78                 26,64                   31,30                    
C006 5,70                         0,13                   15,30               67,08                   11,79                    
C007 17,45                       0,89                   15,06               64,20                   2,40                      
C008 11,43                       0,37                   24,85               3,63                     59,72                    
C009 33,57                       1,87                   9,24                 10,96                   0,01                   44,35                    
mean value 23,16                       0,98                   9,43                 34,76                   0,01                   31,66                    
standard deviation 12,55                       0,67                   7,61                 22,51                   18,32                     
Table 4 Relative amount of bacterial subgroups 
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Figure 5 (A) Relative amount of bacteria in oncology patients in comparison to 
healthy individuals. (B) Comparison of samplings during chemotherapy with 
samplings out of chemotherapy 
 
Figure 5 A shows differences between groups concerning the subgroups 
Clostridium cluster IV and XIVa. While oncology patients had significantly more 
(p = 0.02) Clostridium cluster IV, controls had more Clostridium cluster XIVa. 
 
Graph B in figure 4 points out differences in faecal microbiota composition at 
time points during chemotherapy compared to time points out of chemotherapy. 
The mean percentage of Clostridium cluster IV at time points during 
chemotherapy was 22 ± 10 %, compared to time points out of chemotherapy 
with 14 ± 9 % of all analyzed bacteria.  Hence, there is a significant difference 
(p = 0.01). The average amount of bacteroides, bifidobacteria and Clostridium 
cluster XIVa were 30 ± 12%, 1.2 ± 1.7% and 22 ± 11% at time points during 
chemotherapy and 28 ± 12%, 1.6 ±1.5% and 24 ± 17% at time points out of 
chemotherapy. 
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6.1.3 PCR-DGGE diversity assessment and statistical interpretation 
The mean number of bacterial bands per patient receiving chemotherapy was 
21.8 ± 5 (Figure 6), for clostridium cluster IV 9 ± 5 bands (Figure 7) and for 
clostridium cluster XIVa 14.9 ± 7 bands (Figure 8). DGGE profiles of healthy 
controls had 23.1 ± 5 bands for bacteria, 9 ± 5 for clostridium cluster IV and 
18.9 ± 7 for Clostridium cluster XIVa. 
 
 
Figure 6 DGGE fingerprinting of bacteria 
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Figure 7 DGGE fingerprinting of Clostridium cluster VI 
 
Figure 8 DGGE fingerprinting of Clostridium cluster XIVa 
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The amount of bands as well as Shannon and Simpson diversity indices (Figure 
9) show greater diversity of bacteria and Clostridium cluster XIVa in controls. In 
contrast, clostridial cluster IV DGGE fingerprints show greater diversity indices 
in oncology patients compared to controls. During chemotherapy, a significant 
(p = 0.02 for Simpson index, p = 0.03 for Shannon index) decrease in bacterial 
diversity was seen compared to time points out of chemotherapy (Figure 9). 
 
 
Figure 9 Simpson and Shannon diversity indices 
 
Figure 10 displays PCA of Clostridium cluster IV fingerprints. Graph A 
distinguishes between oncology patients (ON) and healthy control patients (C), 
graph B indicates separation of time points out of chemotherapy (O), during 
chemotherapy (T) and control individuals (C) according to their Clostridium 
cluster IV DGGE fingerprints. PCA analysis thus shows distinctive clustering of 
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O and T samples. The red arrows in the plot showing graph C on the right side 
tell us that bands 178.16, 169.81 and others are characteristic for O samples. 
Bands 207.44, 210.53, 208.17, 302.36, 204.66 and 299.79 are characteristic for 
samples T and responsible for the separation of samples T and O. 
 
 
Figure 10 PCA of Clostridium cluster IV DGGE fingerprints; Grey circles 
indicate O, black oval indicates T and grey thin oval indicates control samples 
 
6.2 AGEING RELATED SHIFTS OF THE MICROBIOTA 
TaqMan quantification illustrated that elderly harboured only 69% ± 21.6% of 
the total bacterial load compared to controls. Industrialized elderly harboured 
significantly more Bacteroides than young volunteers (P=0.016). Despite highly 
diverse levels of bifidobacteria among samples, the differences between young 
and elderly study participants were statistically significant (p=0.026). 
Additionally, elderly persons had significantly less members of Clostridium 
cluster IV in their faecal microbiota than young volunteers (p=0.036) 
[ZWIELEHNER et al., 2009]. Figure 11 shows proportions of Bacteroides, 
Bifidobacteria and Clostridium cluster IV of the total bacterial load of 
industrialized elderly and young volunteers. The total amount of bacteria is 
shown relative to the mean counts for healthy young individuals as previously 
published by Zwielehner et al.. 
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Figure 11 Microbiota composition of industrialized elderly and young individuals 
[ZWIELEHNER et al., 2009] 
 
DGGE bandpattern analysis of bacteria showed 16.6 ± 3 bands for 
industrialized elderly and 20 ± 3 bands in controls. An average of 13 bands was 
observed in individual DGGE bandpatterns of bifidobacteria. Fingerprint 
analysis if Bacteroides indicated 7.6 ± 2.5 bands for elderly, whilst young 
probands indicated an average of 9.5 ± 3 bands. Diversity indices (Figure 12) 
showed a tendency to be lower for elderly than for controls. Clostridium cluster 
IV bandpattern analysis yielded an average of 10 ± 3.5 bands for elderly 
persons and 13 ± 3 bands per young individual. Shannon and Simpson diversity 
indices (Figure 12) were significantly (p=0.02) lower for aged than for the young 
people [ZWIELEHNER et al., 2009].  
 
 
Figure 12 Diversity indices according to Simpson and Shannon of young 
individuals and elderly persons published by Zwielehner et al.. Y, young; E, 
elderly; Cl.IV, Clostridium cluster IV; B, Bacteroides; Bif, bifidobacteria 
[ZWIELEHNER et al., 2009]. 
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6.3 BUTYRATE 
The average butyrate concentration for omnivores measured by HPLC was 
0.012136 ± 27% µmol g-1 faeces, for elderly 0.00574 ± 8.7% µmol g-1 faeces 
and for vegetarians 0.00733 ± 0.844% µmol g-1. 
The quantification of Butyryl-CoA CoA-transferase gene indicates significantly 
higher abundance in vegetarians than in omnivores. Using the CoATD primer 
set, vegetarians (7.46 x 108 ± 2.29 x 108 copies/µl) had the highest abundance 
of the Butyryl-CoA CoA-transferase gene. The abundance was significantly 
higher compared to omnivores (5.26 x 108 ± 2.38 x 108 copies/µl; p=0.0001) 
and elderly (p=0.01). The abundance of this functional gene in elderly (5.26 x 
108 ± 2.38 x 108 copies/µl) showed highest variation, being significantly higher 
than those found in omnivores (p= 0.0007) but lower than in vegetarians. 
Quantification with the CTFB primer pair yielded a gene abundance of 4.12 x 
108 ± 1.81 x 108 copies/µl for omnivores, 4.6 x 108 ± 2.51 x 108 copies/µl for 
vegetarians and 3.7 x 108 ± 1.89 x 108 copies/µl for elderly individuals. PCT 
primers show abundances of 8.61 x 108 ± 3.12 x 108 copies/µl for omnivores, 
8.53 x 108 ± 5.28 x 108 copies/µl for vegetarians and 6.55 x 108 ± 4.73 x 108 
copies/µl for elderly. This showed a trend for low abundances in elderly and 
marginally higher abundances in vegetarians, but not significant [HIPPE, 2009]. 
 
 
Figure 13 Butyryl-CoA CoA-transferase gene sequences in faeces of elderly, 
omnivores and vegetarians. 
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7 DISCUSSION 
 
7.1 METHODS 
7.1.1 Study population 
Many study participants had a longer history of different chemotherapeutic 
regimens. Only two individuals had never received any cancer therapy before. 
Furthermore, the types of cancer and the treatment were variable. Therefore, it 
can not be hypothesized, which changes occurred at the beginning of treatment 
cycles. Also patients who did not receive any antibiotics showed similar 
alterations than those under antimicrobial treatment. In conclusion, it can be 
hypothesized that chemotherapeutic intervention itself causes severe 
perturbations of the gastrointestinal microbiota. 
 
7.1.2 Faecal samples 
Faecal microbial communities are composed of autochthonous gut members 
and by transient bacteria; consequently analysis of faecal samples may 
overestimate the actual composition of the GIT microbiota of humans. Besides 
faecal samples, also other intestinal samples such as specimens from the 
human colon, has been determined. Some of these studies suggest that faecal 
samples do not represent the bacterial community in other parts of the GI tract 
[ZOETENDAL et al., 2006, ZOETENDAL et al., 2002]. In contrast, a paper by 
Van der Waaij et al. suggested that colonic microbes are not in direct contact 
with the mucosa and therefore no significant difference was found between 
colonic biopsies and faeces [VAN DER WAAIJ et al., 2005]. However, we chose 
faecal samples to investigate the microbial composition of the intestinal 
microbiota because they are easy to collect, do not involve any ethical issues 
and do reflect shifts in populations [TURRONI et al., 2008]. 
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7.1.3 Culture- vs. culture-independent methods 
In the past, the microbiota of the gut has been monitored by cultivation-based 
techniques, but limitations of these techniques and the development of more 
sensitive and accurate molecular detection methods have brought new insights 
to the field [MATSUKI et al., 2004]. Besides some advantages including the 
possibility to perform biochemical and physiological investigations, classical 
techniques are time consuming and laborious. Moreover, the samples to be 
examined need to be processed immediately while results are greatly affected 
by media and growth conditions [TURRONI et al., 2008]. For this reason, 
culture-independent methods on the basis of 16S rRNA genes were used for 
this study. Currently, PCR with 16SrRNA-based specific primers has been 
applied to microbiota analyses as the most sensitive and rapid method 
[MATSUKI et al., 2004]. 
 
7.1.4 Real time quantitative PCR (qPCR) 
An accurate and successful real time qPCR assay requires great sensitivity, 
specifity and efficiency. Therefore, sensitivity of all PCR reactions was 
determined with stepwise dilutions of standard curve DNA and specifity was 
confirmed using non-target DNA. To ensure a good efficiency, temperature 
profiles for primer pairs were optimized. 
In this study we used type strains Bacteroides thetaiotaomicronT, 
Bifidobacterium longum ssp. longumT and Clostridium difficile as well as the 
clones CL16 and CC34 for quantification of faecal microbiota. However, a 
mixture of different strains for qPCR standards would show a better image of 
the human microbiota because some species might be preferentially amplified. 
Therefore, absolute amounts should be considered as semiquantitative. 
 
7.1.5 DGGE 
Diversity was assessed using the PCR-DGGE method. Each lane of a PCR-
DGGE gel represents a microbial fingerprint of a faecal sample; each band 
within a lane corresponds to 1 bacterial species, although different species may 
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sometimes have the same melting behaviour [VAN VLIET et al., 2009]. Several 
species possess more than one 16S rRNA operon such as Escherichia coliT 
who forms 4 DGGE bands. The limitations of DGGE in microbial analysis have 
been previously explored by Muyzer et al.. Nevertheless, substantial information 
about species composition can be obtained from very complex microbial 
communities by DGGE analysis [MUYZER et al., 1998]. 
 
7.2 RESULTS – CHEMOTHERPY AND ANTIBIOTIC TREATMENT 
In this study we investigated how the use of cancer chemotherapy ± antibiotic 
treatment perturbs the faecal microbial ecosystem over the course of the 
therapy. The core question was if the microbiota is able to return to its original 
profile after chemotherapeutic and antibiotic intervention and if Clostridium 
difficile could be detected more often following therapy. Another question was if 
shifts between bacterial subgroups (Bacteroides, bifidobacteria, Clostridium 
cluster IV and XIVa) occurred during the therapy and some bacterial subgroups 
are more sensitive to chemotherapy than others. 
 
The majority of studies previously done on the effect of chemotherapy on 
human faecal microbiota used standard microbiological culture techniques 
[NYHLEN et al., 2002, STRINGER et al., 2007]. Most other studies focused on 
the colonization with pathogenic bacteria [SCHALK et al., 2009, VAN VLIET et 
al., 2009] in patients with cancer and chemotherapy-induced diarrhea [ABD EL-
ATTI et al., 2009, STRINGER et al., 2007].  
 
The results of the Bacteroides analysis are not in agreement with the results of 
Nyhlèn et al. who showed increased counts of Bacteroides spp. of samples 
obtained during chemotherapy, but a stable microbiota in most patients. 
Discrepancies in changes of the Bacteroides abundance might be due to 
differences in detection techniques, as Nyhlèn et al. used culture-dependent 
methods. Nyhlèn et al. also reported significantly increased counts of yeast in 
patients, making it a focus for further research in immunocompromised patients 
[NYHLEN et al., 2002]. 
36 
 
 
 
The results show significant effects of chemotherapy and antibiotic treatment on 
intestinal microbiota. Despite high individual variations, a significantly lower 
absolute bacterial load in faeces of patients receiving chemotherapy in 
comparison to healthy controls is shown. These findings are in line with data 
from van Vliet et al., who reported 100-fold lower total bacterial numbers during 
chemotherapy treatment than in healthy controls [VAN VLIET et al., 2009]. In 
addition to lower abundance of bacteria and determined bacterial subgroups, 
PCR-DGGE fingerprints indicate lower diversity of bacteria and Clostridium 
cluster XIVa in oncology patients. Faecal microbiota of patients receiving 
chemotherapy decreases after cycles of chemotherapy. After the end of 
chemotherapeutic cycles the magnitude of microbiota recovers within a few 
days sometimes even showing a “rebound-effect”, supporting the hypothesis 
that the microbiota is able to recover after chemotherapeutic intervention. 
Relative numbers of Clostridium cluster IV and XIV show great alterations due 
to chemotherapeutical interventions, while the genera Bacteroides and 
bifidobacteria seem to be less affected. Interestingly, oncology patients 
harboured significantly more Clostridium cluster IV but at lower diversity than 
controls. This suggests that Clostridium cluster IV harbours some species that 
are particularly vulnerable and some that take advantage of disruption by 
chemotherapeutic intervention. 
 
Furthermore, the incidence of Clostridium difficile in subject ON009 and ON011 
was accompanied by a decrease of the genera bifidobacteria and Clostridium 
cluster IV. Bifidobacteria and members of Clostridium cluster IV might – under 
undisrupted conditions- hold Clostridium difficile at bay, or the higher presence 
of bifidobacteria enhances the barrier function of the gut epithelium that much 
that Clostridium difficile cannot reproduce. Another possibility is that Clostridium 
difficile overgrows bifidobacteria and members of Clostridium cluster IV. These 
bacterial subgroups (bifidobacteria, Clostridium cluster IV and Clostridium 
difficile) might occupy the same niche and Toxin A and B produced by 
Clostridium difficile could suppress bifidobacteria and Clostridium cluster IV. But 
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this phenomenon was only found in two patients. Therefore, more study 
participants are needed to support this hypothesis.  
 
As mentioned above, some study participants received antibiotics whilst others 
did not. Also patient who did not receive any antibiotics showed similar 
alteration than those under antimicrobial therapy. Thus, we conclude that 
chemotherapeutic intervention itself causes severe perturbations of the gastro-
intestinal microbiota. Van Vliet et al. tested the effect of chemotherapy in vitro 
and showed a direct bacteriostatic effect of chemotherapeutics on bacterial 
growth [VAN VLIET et al., 2009]. 
 
This study/thesis showed that changes and shifts in human microbiota occur 
during chemotherapy and that some genera seem to be more affected than 
others. Further research will have to be done to investigate possible prebiotic 
interventions for maintaining gut health during chemotherapeutic and/or 
antibiotic treatment. The emergence of Clostridium difficile and the decrease of 
some genera could be shortened or even avoided. 
 
7.3 RESULTS – AGING MICROBIOTA 
To compare patterns in several microbial genera of the gastrointestinal tract 
between industrialized elderly and young healthy volunteers, a combined 
molecular approach was used, as previously described in this thesis. PCR-
DGGE was used to compare diversity of bacteria, Clostridium cluster IV, 
bifidobacteria and Bacteroides. qPCR was used to quantify abundance of these 
bacterial subgroups [ZWIELEHNER et al., 2009]. 
 
Faeces of elderly had less total bacteria and lower bacterial diversity compared 
to that of the young subjects. Samples of industrialized elderly showed an 
increase in the relative abundance of Bacteroides, although this group 
displayed less diversity than in young subjects. Significantly higher abundance 
of bifidobacteria and Clostridium cluster IV was shown for young volunteers, 
also showing a grater diversity [ZWIELEHNER et al., 2009]. 
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Previous studies also reported a reduction of diversity of bifidobacteria 
associated with ageing [HOPKINS et al., 2002, WOODMANSEY et al., 2004] 
and hospitalization of the elderly [BARTOSCH et al., 2004]. The elderly study 
population used for the study by Zwielehner et al. was supplemented with 
soluble fibre, but this prebiotic intervention was apparently not able to 
antagonize ageing-related shifts in bifidobacteria [ZWIELEHNER et al., 2009]. 
 
The elderly study population showed a relative increase in abundance of 
Bacteroides, whilst others [BARTOSCH et al., 2004, HOPKINS et al., 2002, 
WOODMANSEY et al., 2004] reported a decrease in the relative abundance of 
this group. However, all the previous studies reported a decrease of diversity of 
this group, like the study by Zwielehner et al. [ZWIELEHNER et al., 2009].  
 
Reduced numbers of Bacteria in the faeces of elderly may reflect the 
physiological changes associated with ageing. These include prolonged colonic 
transit time and reduced dietary energy requirement and food uptake. 
Furthermore, reductions of important genera like Clostridium cluster IV and 
bifidobacteria might result in decreased formation of SCFAs and altered barrier 
function of gut epithelium in elderly. These changes associated with ageing, 
have been described  to cause impaired immune functions and may result in a 
greater susceptibility to disease [ZWIELEHNER et al., 2009]. 
 
7.4 RESULTS – BUTYRATE AND BUTYRYL-COA COA-TRANSFERASE 
GENE 
Diet and age are known to influence the production and consumption of SCFAs.  
Therefore the study done by Hippe et al. compared SCFAs in faeces using 
HPLC-RI and Butyryl-CoA CoA-transferase gene abundance using different 
sets of degenerated primers and real time quantitative PCR [HIPPE, 2009]. 
 
As mentioned above, sets of degenerated primers were used in this study. 
Some species might not be detected, even if they are present in high numbers, 
as not from all of the butyrate producing bacteria the Butyryl-CoA CoA-
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transferase gene loci is known. Therefore, these primer pairs cover just several 
butyrate producing bacteria, described by Flint et al., 2006 [HIPPE, 2009]. 
 
The highest butyrate concentrations were found in faeces of the mixed diet 
group; vegetarians had 66.7% lower concentrations and the geriatric group 
showed 71.43% lower concentrations of butyrate in their faeces [HIPPE, 2009]. 
 
Compared to the mixed diet group, in vegetarians significant more Butyryl-CoA 
CoA-transferase genes (CoATD +191.43%; CTFB +11.86%; PCT+12.5%) were 
found. In geriatric subjects with one primer set significant more (CoATD 
+105.7%) and with two primer sets less (CTFB -10% and -20%) abundance of 
Butyryl-CoA CoA-transferase gene was detected. These results might be due to 
higher counts of bacteria (12%), Clostridium cluster lV (+1.4%) and Bacteroides 
(+7.46%) in the vegetarian group [LISZT et al., 2009], which are known to be 
butyrate producers. The geriatric subject group had 31% fewer bacteria, while 
the amounts of Bacteroides and Clostridium cluster IV were higher compared to 
mixed diet group. Bifidobacteria were almost the same with 0.8% lower 
amounts for the geriatric subject group [HIPPE, 2009]. 
 
The in situ production of total SCFAs is difficult to determine because more than 
95% of SCFAs are rapidly absorbed by the host [MCFALL-NGAI, 2007]. As a 
result, faecal concentrations of SCFAs are not necessarily representative of 
concentrations in the colon and can also be affected by intestinal transit time 
[LEWIS et al., 1997]. Another possibility for fewer concentrations may be the 
butyrogenic effect [HIPPE, 2009]. 
 
Equal to the study discussed before, the elderly group was supplemented with 
soluble fibre and may resulted in increased Butyryl-CoA CoA-transferase gene 
abundance and increased butyrate concentrations in their faeces [HIPPE, 
2009]. 
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Hippe et al. analyzed the same study groups as Zwielehner et al., 2009 and 
Liszt et al., 2009. The results of Zwielehner et al. and Liszt et al. can be linked 
to the results of Hippe et al.. Liszt et al. reported 12% higher counts of bacterial 
DNA for vegetarians than for omnivores. The mean proportion of Clostridium 
cluster IV in faeces of vegetarians was 37.2 ± 17.00% and in omnivores 36.64 ± 
14.22%. The average percentage of Bacteroides in vegetarians was 28.72 ± 
10.35% and in omnivores 21.26 ± 8.05%. Bifidobacteria were found to make up 
1.52 ± 1.29% in vegetarians and 1.59 ± 1.73% in omnivores [HIPPE, 2009, 
LISZT et al., 2009]. 
 
8 SUMMARY 
 
The gastrointestinal tract can be regarded as a very complex ecosystem 
involving interplay between food, host cells and microbes. Microbes inhabiting 
the human intestine (known as the microbiota) play several significant roles in 
the digestion of food, generation of short chain fatty acids and prevention of 
colonization by pathogens. As a balanced and ‘healthy’ microbiota is important 
for maintaining human health, strong evidence has emerged of substantial 
modifications during illness (chronic and degenerative diseases including IBD, 
Crohn’s disease, colon cancer and rheumatoid arthritis) or exposure to 
threatening experiences, such as antibiotics and chemotherapy. 
 
Although many factors are known to influence the intestinal microbiota, this 
thesis focuses on diet and SCFAs, ageing and the impact of chemotherapy and 
antibiotics. This thesis discusses and links the manuscripts by Hippe et al. and 
Lassl et al. and the already published article by Zwielehner et al., which can be 
found in the appendix of the present thesis. However, the main focus of this 
diploma thesis is on analyzing the microbiota during chemotherapy and 
antibiotic treatment. 
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All of these papers used culture independent methods. Abundance of bacteria, 
Bacteroides, bifidobacteria, Clostridium cluster IV and XIVa as well as 
Clostridium difficile was determined using real time quantitative PCR with 
TaqMan detection. Real time PCR with Sybr-green detection and sets of 
degenerate primers were used by Hippe et al. for Butyryl-CoA CoA-transferase 
gene abundance measurement. Diversity was assessed applying PCR-DGGE. 
Furthermore, HPLC-RI was used for detecting faecal concentrations of butyrate. 
 
Ageing and diet are known to alter the composition of gut microbiota. Therefore, 
faeces of three study populations (industrialized elderly, young omnivores and 
young vegetarians) were analyzed regarding their butyrate concentration and 
abundance of Butyryl-CoA CoA-transferase genes by Hippe et al.. The Butyryl-
CoA CoA-transferase gene is involved in the butyrate production of some 
bacteria and butyrate, as major energy source for the gut epithelium seems to 
play an important role for colonic health.  
 
Abundance of Butyryl-CoA CoA-transferase gene increases from omnivores, 
over elderly to the group of vegetarians, while the average butyrate amount in 
faeces from HPLC analysis decreases from omnivores, over vegetarians to 
geriatric population. This study shows that age and diet influences the 
microbiota and the abundance of butyrate in faeces. 
 
The populations of industrialized elderly and young omnivores were also part of 
the study by Zwielehner et al.. This study aimed at determining ageing-related 
shifts in diversity and composition of key members of the faecal microbiota. 
Bacteria, Bacteroides, bifidobacteria and Clostridium cluster IV were assessed 
using a combination of molecular methods. 
The industrialized elderly harboured significantly higher numbers of Bacteroides 
than controls (p=0.016) but contained less bifidobacteria (p=0.026) and 
Clostridium cluster IV (p=0.036). The elderly showed less total bacteria diversity 
and less diversity with the Clostridium cluster IV and Bacteroides. These 
analyses indicate a less diverse microbiota in elderly.  
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The main purpose of this study/thesis was to investigate changes within the GI 
microbiota in response to chemotherapy and antibiotics by assessing diversity 
and abundance of bacteria, Bacteroides, bifidobacteria, Clostridium cluster IV 
and XIVa and Clostridium difficile at four time points in comparison to healthy 
controls. Therefore, this study aimed to detect shifts in intestinal microbiota, 
which enable pathogenic Clostridium difficile to emerge. Furthermore, the 
resilience after chemotherapy was investigated. 
 
Patients receiving chemotherapy harboured only 25 ± 22% of the absolute 
bacterial load in their faeces compared to healthy controls. After the end of 
chemotherapeutic cycles the magnitude of microbiota recovers within a few 
days sometimes even showing a “rebound-effect”. The chemotherapeutical 
treatment has marginally affected the genera Bacteroides and bifidobacteria 
while the genera Clostridium cluster IV and XIVa seem to be more sensitive. 
While oncology patients harboured significantly more (p = 0.02) Clostridium 
cluster IV, controls had more Clostridium cluster XIVa. The incidence of 
Clostridium difficile in two subjects was accompanied by a decrease of the 
genera bifidobacteria and Clostridium cluster IV. PCR-DGGE fingerprinting 
analysis report decreased diversity of bacteria and Clostridium cluster XIVa in 
response to medical treatment and compared to healthy individuals. In 
conclusion, chemotherapy treatment causes changes in faecal microbiota, 
which coincides with the development of Clostridium difficile infection in some 
patients. 
 
Altogether, the present thesis shows that diet, ageing and medical treatment 
such as chemotherapy and antibiotics alter the microbiota of the host organism. 
As a result, health promoting functions of the microbiota, e. g. SCFAs 
production is affected. Changes in GI microbiota are linked to impaired immune 
functions in elderly and immunocompromised subjects and may result in a 
greater susceptibility to disease and infection. Prebiotic intervention might be a 
promising concept to modify the microbiota of aged and immunocompromised 
patients to bring safe health benefits.  
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9 ZUSAMMENFASSUNG 
 
Mikroorganismen welche den menschlichen Darm besiedeln (Darmmikrobiota) 
sind eng mit dem Wirtsorganismus verbunden und stellen ein komplexes 
Ökosystem mit einer Vielzahl an Funktionen dar. Die Unterstützung der 
Verdauung, Immunmodulation, Synthese von Vitaminen und Produktion von 
Buttersäure zur Energieversorgung der Darmepithelien sind nur einige der 
Aufgaben, welche das Mikrobiota für den Wirtsorganismus erfüllen. Eine 
ausgeglichene und ‚gesunde’ Mikrobiota ist zusätzlich notwendig um das 
Wachstum von pathogenen Mikroorganismen, wie in etwa Clostridium difficile 
im Zaum zu halten und ist deshalb für die Gesunderhaltung des Menschen von 
enormer Bedeutung. In der Vergangenheit wurden auch Zusammenhänge 
zwischen Erkrankungen (chronisch entzündliche Darmerkrankung, Morbus 
Crohn, Darmkrebs, Rheumatoide Arthritis, Adipositas, ect.) und einer 
veränderten Darmmikrobiota gefunden. Weiters haben Medikamente, wie 
Zytostatika im Rahmen einer Chemotherapie und Antibiotika einen merklichen 
Einfluss auf die Zusammensetzung des Mikrobiota.  
 
Die vorliegende Diplomarbeit beschäftigt sich mit den Zusammenhängen 
zwischen der Darmmikrobiota und dem Einfluss der Ernährung und Butyrat, 
dem Einfluss des Alterns und dem Einfluss von Chemotherapie und Antibiotika. 
Diese Arbeit gibt einen Überblick über die im Anhang zu findenden Manuskripte 
von Hippe et al. und Lassl et al., sowie dem veröffentlichten Artikel von 
Zwielehner et al.. Das Hauptaugenmerk dieser Arbeit liegt jedoch in der 
Analyse des menschlichen Mikrobiota während Chemo- und Antibiotikatherapie. 
 
Alle Analysen wurden mit Hilfe von Kultur-unabhängigen Methoden 
durchgeführt. Das Vorhandensein von Bakterien, Bacteroides, bifidobakterien, 
Clostridium cluster IV, XIVa und Clostridium difficile im Stuhl wurde mit real time 
PCR (TaqMan-Detektion) analysiert. Diversitätsanalysen wurden mit PCR-
DGGE durchgeführt. Einzig das Vorhandensein des Butyryl-CoA CoA-
transferase Gens wurde anhand eines Sybr-green Systems für real time PCR 
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nachgewiesen, während die Buttersäure-konzentrationen im Stuhl mit HPCL-RI 
gemessen wurden.  
 
Hippe et al. untersucht Stuhl von drei verschiedenen Populationen (Geriatriker, 
junge Mischköstler und junge Vegetarier) hinsichtlich Buttersäure-
konzentrationen und dem Vorliegen des Butyryl-CoA CoA-transferase Gens. 
Die Butyryl-CoA CoA-transferase spielt eine Rolle bei der bakteriellen 
Produktion von Buttersäure, welche als Faktor für die Gesunderhaltung des 
Darms gilt. 
 
Das Butyryl-CoA CoA-transferase Gen wurde am häufigsten in der Gruppe der 
Vegetarier gefunden, gefolgt von Geriatrikern und Mischköstlern. Im Gegensatz 
dazu wurde die höchste Buttersäure-konzentration im Stuhl von Mischköstlern, 
gefolgt von Vegetariern und Geriatrikern festgestellt. Diese Ergebnisse zeigen 
eine vermehrte Ansiedelung von Buttersäure-produzierenden Bakterien im 
Darm von Vegetariern. Das vermehrte Vorkommen von Buttersäure im 
Darmlumen könnte laut Hippe et al. die Vermehrung von Bakterien 
unterstützen, welche Butyrat als Substrat verwenden und deshalb zu 
verminderten Buttersäure-konzentrationen im Stuhl führen.  
 
Weiters wurde die Gruppe der Geriatriker mit jener der jungen Mischköstler von 
Zwielehner et al. untersucht, um alterungs-relevante Veränderungen des 
Mikrobiota zu bestimmen. Zu diesem Zwecke wurden das Vorkommen und die 
Diversität von Bakterien, Bacteroides, bifidobakterien und Clostridium cluster IV 
analysiert. 
 
Zwielehner et al. konnte signifikant mehr Bacteroides (p=0.016), jedoch weniger 
bifidobakterien (p=0.026) und Clostridium cluster IV (p=0.036) im Stuhl von 
Geriatrikern im Vergleich zu Kontrollpersonen nachweisen. Ältere Personen 
zeigten außerdem eine verringerte Diversität hinsichtlich der Gruppen 
Clostridium cluster IV und Bacteroides. Diese Resultate zeigen ein verändertes 
und weniger diverses Mikrobiota im Stuhl älterer Personen. 
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Hauptsächlich fokussierte diese Arbeit jedoch auf Veränderungen und 
Verschiebungen innerhalb des Mikrobiota aufgrund von Chemotherapie und 
Antibiotika. Daher wurden Diversität und Vorhandensein von Bakterien, 
Bacteroides, bifidobakterien, Clostridium cluster IV und XIVa sowie Clostridium 
difficile zu vier verschieden Zeitpunkten der Therapie untersucht. Die 
wichtigsten Fragestellungen lauteten in diesem Zusammenhang: Ist das 
Mikrobiota nach Chemotherapie fähig sich zu erholen bzw. seine ursprüngliche 
Zusammensetzung wieder zu erlangen? Und kann im Laufe der Therapie das 
Heranwachsen von Clostridium difficile beobachtet werden? 
 
Bei Chemotherapie-patienten konnten im Verglich zu Kontrollpersonen nur 25 ± 
22% an Bakterien im Stuhl nachgewiesen werden. Die Behandlung mit 
Zytostatika zeigte wenige Veränderungen hinsichtlich Bacteroides und 
Bifidobakterien, während Clostridium cluster IV und XIVa merkliche 
Veränderungen zeigten. Interessanterweise konnten bei Chemotherapie-
patienten signifikant mehr (p=0.02) Clostridium cluster IV nachgewiesen 
werden, während Clostridium cluster XIVa in größerer Anzahl im Stuhl von 
Kontrollpersonen zu finden war. Nach Chemotherapie konnte sich das 
Mikrobiota, nach einem gesamten Absinken, häufig wieder auf Ausgangsniveau 
und auch darüber hinaus erholen. Das Vorkommen von Clostridium difficile 
konnte bei zwei Chemothrapie-patienten beobachtet werden. DGGE-Analysen 
des Mikrobiota von Chemotherapie-patienten konnte eine verringerte Diversität 
bei Bakterien und Clustridium cluster XIVa feststellen.  
 
Abschließend konnten diese Ergebnisse zeigen dass Alter, Ernährung und der 
Einfluss von Medikamenten wie Zytostatika und Antibiotika einen erheblichen 
Einfluss auf Zusammensetzung und Diversität des Darmmikrobiota haben. 
Folglich kann eine Vielzahl an gesundheitsfördernden Funktionen des 
Mikrobiota beeinträchtigt sein. Inwieweit eine prebiotische Supplementierung 
die Wiederherstellung bzw. Erhaltung einer ‚gesunden’ Mikrobiota bei älteren 
und immunsupprimierten Patienten beeinflussen kann, ist Gegenstand der 
Forschung in nächster Zukunft.  
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ABSTRACT 
Chemotherapy and antibiotics have been shown to disturb the host’s protective 
gastrointestinal microbiota, thereby increasing susceptibility to infection. We 
investigated consequences of chemotherapy ± antibiotics in cancer treatment 
on abundance and diversity of dominant faecal microbiota. 
Faeces of 11 ambulant patients receiving chemotherapy ± accompanying 
antibiotics were analyzed before and after treatment at four time points in 
comparison to 9 gender-, age- and lifestyle-matched healthy controls. We 
targeted 16S rRNA genes of bacteria, Bacteroides, bifidobacteria, Clostridium 
cluster IV and XIVa as well as Clostridium difficile with TaqMan-qPCR. 
Furthermore, we assessed diversity of bacteria, Clostridium clusters IV and 
XIVa at the four sampling points using denaturing gradient gel electrophoresis 
(DGGE) fingerprinting. 
Abundance of faecal microbiota decreases significantly after administration of 
chemotherapeutics as well as in comparison to healthy controls. The 
abundance of microbiota recovers within a few days sometimes even showing a 
“rebound-effect”. Treatment led to a significant increase of relative abundance 
of Clostridium cluster IV and a decrease of Clostridium cluster XIVa. 
Bacteroides and bifidobacteria were marginally affected. In addition, diversity of 
bacteria and Clostridium cluster XIVa decreased in response to treatment and 
in comparison to healthy individuals. In two out of eleven patients Clostridium 
difficile emerged. 
Despite high individual variations these results suggest that abundance and 
diversity of gastrointestinal microbiota, especially Clostridium cluster XIVa 
following treatment facilitate growth of emerging pathogens, such as Clostridium 
difficile.  
 
INTRODUCTION 
The intestinal ecosystem constitutes the microbiota that can be “pictured as a 
microbial organ placed within a host organism”. This ecosystem involves a 
dynamic interplay between food, host cells and microbes [TURRONI et al., 
2008]. Recent studies reveal that major mammalian metabolic processes are 
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under symbiotic homeostatic control [MARTIN et al., 2009]. The microbiota is 
significantly involved in the digestion of food, energy regulation, generation of 
short chain fatty acids (SCFAs), vitamin synthesis, prevention of pathogen 
colonization and protection against cell injury [BACKHED et al., 2005, DE LA 
COCHETIERE et al., 2005, ECKBURG et al., 2005, TLASKALOVA-
HOGENOVA et al., 2004, TURNBAUGH et al., 2009]. 
The faecal microbiota is dominated by the Clostridium coccoides group - 
Clostridium cluster XIVa (lately reclassified by Liu et al. as Blautia coccoides) 
the Clostridium leptum group - Clostridium cluster IV and Bacteroides group 
[LIU et al., 2008, MAUKONEN et al., 2008]. All three groups are known to 
positively affect the gut health through nutrient absorption, production of short 
chain fatty acids (SCFAs) and epithelial cell maturation [MAUKONEN et al., 
2006, WOODMANSEY, 2007]. Abundance and diversity of dominant bacteria 
are affected by ageing and diet [LISZT et al., 2009, ZWIELEHNER et al., 2009]. 
 
Innate immunity, mechanical mucosal barrier and colonization resistance 
prevent the invasion of endogenous bacteria from oral cavity and the 
gastrointestinal tract [VAN VLIET et al., 2009]. Changes of Firmicutes and 
Bacteriodetes and weakened barrier function is currently discussed for complex 
diseases such as metabolic syndrome and atopy [LEY et al., 2005, SUZUKI et 
al., 2008]. 
 
Chemotherapy and the use of antibiotics damage the mucosal cells of the 
gastrointestinal tract and disrupt the ecological balance of the microbiota, 
allowing pathogens such as Clostridium difficile to emerge [GUARNER et al., 
2003, NYHLEN et al., 2002]. Clostridium difficile is thought to be the causative 
agent in up to 20% of antibiotic-associated diarrhoea (AAD) patients [KONING 
et al., 2008].  
Approximately 40% of patients receiving standard dose chemotherapy and 
100% of patients receiving high dose chemotherapy and stem cell or bone 
marrow transplantation have been described to suffer from abdominal pain, 
ulceration, bloating and vomiting [STRINGER et al., 2007, STRINGER et al., 
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2009]. Although gastrointestinal disturbances (mucositis, diarrhoea and 
constipation) and immunosuppression are well recognised side-effects of 
cancer treatment, very little research has been dedicated to changes in the 
microbiota composition. Because of these changes, absorption and other 
intestinal functions of the microbiota may also be altered [GIBSON et al., 2006].  
 
Whereas consequences of disturbed GI microbiota are generally accepted, 
changes of the microbial balance which allow emergence of pathogens need to 
be better defined.  
We analyzed the course of faecal microbiota of patients receiving cancer 
chemotherapy ± antibiotics in comparison to healthy control individuals. We 
focused on abundance and diversity of dominant bacteria, Bacteroides, 
bifidobacteria, Clostridium cluster IV, Clostridium cluster XIVa and Clostridium 
difficile using culture-independent methods. Changes in populations were 
analyzed for the ability to return to its original composition (resilience) after 
chemotherapy and the emergence of Clostridium difficile. 
 
MATERIAL AND METHODS 
Study participants and study design 
Eleven subjects receiving chemotherapy ± antimicrobial therapy (aged 55 ± 14 
years, BMI 28 ± 7) from the Sozialmedizinisches Zentrum Ost in Vienna and 
nine healthy individuals (aged 55 ± 21 years, BMI 24 ± 5) joined this study. 
Faecal samples of each ambulant oncology patient were collected at four time 
points before, during or after the onset of treatment within two weeks. The term 
“after chemotherapeuty” is used in the following sections for sampling points 
after chemotherapeutic intervention (1 – 7 days after). Two out of nine patients 
had never received any chemotherapy before, while the others had a longer 
history of chemotherapy. Stool samples of healthy individuals were collected 
once.  
We interviewed all study participants assessing: age; gender; body length; 
weight; health status (chronic and acute diseases); life-style aspects such as 
cigarette and alcohol consumption as well as physical activity.  Dietary habits 
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were assessed using a food frequency questionnaire. Exclusion criteria for 
healthy controls were (a) antimicrobial medication (b) chemotherapeutic 
treatment and (c) pre- and probiotics for at least three months before the 
collection of faecal samples. One subject receiving chemotherapy additionally 
suffered from rheumatism while another subject suffered from diabetes mellitus 
type II, hypertension and obesity. Study populations were gender balanced, with 
55% females in both, oncology patients and healthy controls.  
Furthermore, patients’ medical records reported chemotherapeutic and 
antimicrobial treatment. All subjects gave written informed consent. The study 
was approved by the ethics committee of Vienna. 
 
Stool sample processing 
After collection, stool samples were brought to the laboratory and immediately 
stored at  -70°C. A 200 mg aliquot of each sample was treated twice for 45 s in 
a bead-beater (Mini-Beadbeater-8). Thereafter DNA was extracted using the 
QIAamp® DNA Stool Mini Kit (QIA-GEN) following the manufacturer’s protocol. 
Finally we stored the DNA at -20°C until the analysis was conducted. 
 
Type strains 
We used type strains, knowing to be a part of the human gastrointestinal 
microbiota and cloned sequences to design a DGGE standard lane marker. 
Type strains Bacteroides thetaiotaomicron DSM 2079T, Enterococcus faecium 
DSM 20477 T, Lactobaccilus reuteri ATCC 55730 T, Bifidobacterium longum ssp. 
longum DSM 20097 T, Escherichia coli IMBH 252/07 and clones CL16 and 
CC34 (see below) were used creating a comparable standard lane marker for 
DGGE gels analyzing all bacteria (Fig. 3). 
 
Clone library 
To create a standard lane marker for DGGE analysis and to identify dominant 
members of the Clostridium cluster XIVa we constructed a clone library from 
stool samples. For this purpose PCR products amplified with primers 195-F 
[MEIER et al., 1999] and Ccocc-R [MATSUKI et al., 2004] were inserted into a 
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p-GEM Easy Vector (Promega) following the instructions of the manufacturer. 
We picked fourty clones, amplified with primer pair T7/Sp6 (Promega) and 
checked fragment length on 2% agarose gel before clone inserts were 
sequenced by ‘DNA confidence’ (Vienna). Finally, nucleotide sequences were 
corrected for primer and vector sequences in CodonCodeAligner 
(www.codoncode.com) and taxonomically identified using the ribosomal 
database project (http://rdp.cme.msu.edu/). The clone library used for creating a 
standard lane marker for DGGE analysis of Clostridium cluster IV has 
previously been described [ZWIELEHNER et al., 2009].  
 
PCR-DGGE-fingerprinting 
DGGE was performed as described by Muyzer et al. [MUYZER et al., 1993]. 
Primer pairs and annealing temperatures to analyze the diversity of (a) bacteria, 
(b) Clostridium cluster IV and (c) Clostridium cluster XIVa are described in 
Table 2. The PCR reaction mixture consisted of ready-to-use mastermix 
(Promega) with1.5 mM MgCl2, 500 nmol/L of both primers and 2 µl of template 
DNA. When amplifying faecal samples, bovine serum albumin (Fermentas) was 
added to a final concentration of 400µg/ml. We used a Robocycler (Stratagene) 
for all amplifications. 
PCR products were separated by polyacrylamid gels with a denaturing gradient 
of 30-60% for predominant bacteria, 30-50% for Clostridium cluster IV and 35-
50% for Clostridium cluster XIVa using a gradientmixer (Hoefer SG 30) and a 
peristaltic pump. Electrophoresis was performed for 9 h at 129 V at 60°C 
(predominant bacteria), 5 h at 200V at 60°C (Clostridium cluster IV) and 7 h at 
200 V at 60°C (Clostridium cluster XIVa). We created a standard lane marker 
for each DGGE analysis assay to ensure reliable gel-to-gel comparison. These 
standard lane markers (described above) were loaded in triplicate on each gel 
to adjust gradient-variations within one gel.  
 
Quantitative TaqMan-PCR 
The abundance of bacteria and bacterial subgroups was measured by 16S 
rRNA gene-targeting TaqMan qPCR. Optimal annealing temperature of the 
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PCR primer pairs and expected product sizes (Table 1) were ascertained using 
a Robocycler (Stratagene), before the TaqMan-assay was performed in a 
Rotorgene 3000 (Corbett Life Science). We analyzed each sample in duplicate. 
Briefly, amplification reactions were carried out in a total volume of 10µl 
consisting of 5µl Taq-Man SensiMix DNA Kit (Quantance), 1µl of each primer 
and Taq-Man-probe (concentrations in a final volume of 10µl see table 1) and 
10ng of bacterial DNA. Amplification programs included an initial denaturation at 
95°C for 10 min followed by 40 cycles of denaturation step at 95 °C for 30 s, 
primer annealing at 55 °C (bacteria, Clostridium cluster IV), 56 °C (Clostridium 
cluster XIVa), 58 °C (Clostridium difficile) or 60 °C (bacteroides, Bifidobacteria) 
for 30 s and extension at 72 °C for 50 s.  
We used tenfold serial DNA dilutions of type strains Bacteroides 
thetaiotaomicronT, Bifidobacterium longum ssp. longumT and Clostridium 
difficile as well as the clones CL16 and CC34 and one faecal sample to 
construct standard curves for comparison of PCR reaction efficiencies among 
different experiments.  
We quantified DNA of Bacteroides thetaiotaomicronT, Bifidobacterium longum 
ssp. longumT and Clostridium difficile, using the nanodrop method and 
calculated DNA copies/µl through mean G+C content of each strain. 
Quantification of clones CL16 (Clostridium leptum 16) and CC34 (Clostridium 
coccoides 34) was done determining the numbers of CFU (colony forming 
units). Relative percentages of bacterial subgroups were calculated in relation 
to total rRNA gene copies amplified with primer pair BAC-338-F and BAC-805-R 
[YU et al., 2005].  
Sensitivity of PCR reactions was determined with stepwise dilutions of standard 
curve DNA. The specifity was confirmed using non-target DNA. 
 
Statistical analysis 
Statistical evaluation of differences between groups (chemotherapy and control) 
and changes within the chemotherapy group (time points before chemotherapy, 
time points after chemotherapy) was carried out using the OriginPro version 8 
(OriginLab, Northampton, MA). For two group comparisons of independent 
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ordinal and interval values we used the two-sample-T-test and the 
nonparametric Mann-Whitney-U-test. For the analysis of related data we used 
the paired-sample-T-test or the non-parametric Wilcoxon-signed-ranked-test. P 
values below 0.05 were considered statistically significant. 
We analyzed PCR-DGGE bands in GelComparII (www.applied-maths.com) and 
compared band tables with principal component analysis (PCA) using the 
default settings in ‘R-software environment for statistical computing’ (www.r-
project.org) until 100% variance was explained. Clustering was performed 
applying Dice coefficient and UPMGA dendrograms. Shannon and Simpson 
diversity indices were calculated on quantitative band information with the 
default settings implemented in the ‘vegan’ package in ‘R’. Shannon index is 
defined as H = -∑ pi ln pi, where pi is the proportional abundance of species i. 
For Simpson index, given as 1 - D, this is 1 - ∑(( pi)^2), pi is the relative 
frequency of the i-th species [ZWIELEHNER et al., 2009]. In short, the higher 
the Simpson (0-1) and Shannon indices are, the higher the diversity.  
 
RESULTS 
Dietary aspects 
We assessed the participants` dietary habits using a food frequency 
questionnaire. All study participants (patients and controls) were omnivores and 
showed similar consumption patterns of liquids, alcohol, fruits, vegetables, 
grains and milk products. Healthy controls stated more frequent consumption of 
fruits as well as whole grain products and alcohol several times a week 
compared to patients receiving chemotherapy (not significant). 
 
Chemotherapeutic treatment ± antibiotics decreases absolute bacterial 
numbers in comparison to healthy controls 
To investigate whether chemotherapy ± antibiotics change the human faecal 
microbiota composition over time and in contrast to healthy individuals, we 
investigated absolute numbers and relative percentages of bacterial subgroups. 
The ambulant patients receiving chemotherapy harboured only 25 ± 22% of the 
absolute bacterial load in their faeces compared to healthy controls. This overall 
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decrease affected Bacteroides, bifidobacteria, Clostridium cluster IV and XIVa. 
Despite high inter- and intraindividual variations among samples, the 
differences in absolute numbers of bacteria (p = 0.02), Bacteriodes (p=0.01), 
bifidobacteria (p=0.001) and Clostridium cluster XIVa (p=0.001) were 
statistically significant. Furthermore, patients receiving chemotherapy had less 
absolute numbers of Clostridium cluster IV (not significant). The decrease of all 
bacterial subgroups within 3 – 6 days after chemotherapeutic intervention was 
in some cases followed by a rebound of bacterial abundance within 5 – 9 days 
(Figure 1). One subject showed a drastic decline of all analyzed bacteria, 
following treatment due to blood stem cell transplantation. 
 
Clostridium cluster IV and XIVa show great alterations due to 
chemotherapeutic intervention 
The mean proportion of Bacteroides in stool samples was 27 ± 12% in 
chemotherapy patients and 23 ± 12% in healthy individuals. The mean 
percentage of bifidobacteria in patients was 1.17 ± 1% and 1% ± 0.7% in 
controls. Patients harboured 16 ± 11% of Clostridium cluster IV and 20 ± 14% of 
Clostridium cluster XIVa, while controls harboured 10 ± 7% and 34 ± 22% of 
clostridial clusters IV and XIVa (Figure 2). Subgroups wete quantified as 
percentage of total bacterial DNA. 
A difference between patients receiving chemotherapy and control group 
concerning the subgroups Clostridium cluster IV and XIVa was observed. While 
patients receiving chemotherapy harboured significantly more (p = 0.02) 
Clostridium cluster IV, controls had more Clostridium cluster XIVa (Figure 4A).  
 
Decreased levels of bifidobacteria and Clostridium cluster XIVa and 
increased levels of Clostridium cluster IV after chemotherapeutic 
intervention 
The average amount of bifidobacteria before chemotherapy was 1.6 ± 2 % in 
comparison to 0.8 ± 1.4 % after chemotherapy, but not significant (p=0.06). 
Furthermore, Clostridium cluster XIVa showed a decrease from 23 ± 17 % to 15 
± 9 % comparing time points before Chemotherapy and time points after 
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Chemotherapy. The mean percentage of Clostridium cluster IV at time points 
before chemotherapy was 15 ± 12 %, compared to time points after 
chemotherapeutic intervention (defined in Material and Methods) with 18 ± 14 % 
of all analyzed bacteria. No difference concerning the subgroup Bacteroides 
was observed (Figure 4C). 
 
Clostridium difficile colonization following chemotherapy 
In 18% of patients receiving chemotherapy Clostridium difficile was detected. 
One Patient harboured Clostridium difficile at all time points investigated (of 0.4 
± 0.7 % of total DNA, showing the highest level of 1.22% at sampling point 3, as 
highlighted in Figure 2), after chemotherapeutic and antibiotic treatment. In one 
patient Clostridium difficile emerged at time points 3 (3.90% of total bacterial 
DNA, Figure 2). 
 
Higher bacterial and clostridial XIVa diversity in healthy controls 
DGGE fingerprinting analyses of bacteria, Clostridium cluster IV and Clostridium 
cluster XIVa subgroups show highly diverse datasets in individuals indicating a 
pronounced individual uniqueness of faecal microbiota. The mean numbers of 
bacterial bands per patient receiving chemotherapy were 21.8 ± 5, of 
clostridium cluster IV 9 ± 5 bands and of clostridium cluster XIVa 14.9 ± 7 
bands. DGGE profiles of healthy controls had 23.1 ± 5 bands for bacteria, 9 ± 5 
for clostridium cluster IV and 18.9 ± 7 for clostridium cluster XIVa. The amount 
of bands as well as Shannon and Simpson diversity indices show a higher 
diversity of bacteria and Clostridium cluster XIVa in healthy controls (Figure 5). 
In contrast to bacterial and clostridial cluster XIVa fingerprints, clostridial cluster 
IV DGGE fingerprints show higher diversity indices in patients receiving 
chemotherapy. After chemotherapy a decrease of the bacterial and clostridial 
cluster IV diversity, but a slightly higher clostridial cluster XIVa diversity was 
seen compared to time points before chemotherapy (Figure 5).  
The dataset was subjected to principal component analysis (PCA). PCA 
analysis extracts underlying components of samples according to their variance. 
PCA of Clostridium cluster IV fingerprints indicates separation of time points 
64 
 
 
 
after chemotherapy (O), before chemotherapy (T) and control individuals (C), 
Figure 5. PCA analysis thus shows distinctive clustering of O and T samples. 
Bands 178.16, 169.81 and others are characteristic for O samples. Bands 
207.44, 210.53, 208.17, 302.36, 204.66 and 299.79 are characteristic for 
samples T and responsible for the separation of samples T and O.  
 
DISCUSSION 
Chemotherapy and antibiotics are essential standard therapies in malignant 
diseases but severe side-effects such as mucositis, diarrhoe or constipation are 
often life-threatening [STRINGER et al., 2007]. This treatment severely disturbs 
the host microbiota, host mucosal protection [CROSWELL et al., 2009], thereby 
increasing the risk of infections [VAN VLIET et al., 2009]. Overgrowth of species 
with potential pathogenicity such as toxigenic Clostridium difficile and 
inflammatory complications are among the most-encountered serious 
complications of chemotherapy and antibiotic treatment in cancer patients 
[GUARNER et al., 2003, VAN VLIET et al., 2009]. 
In this study, we investigated how the use of cancer chemotherapy ± antibiotic 
treatment perturbs the faecal microbial ecosystem over the course of the 
therapy. The core questions were if the microbiota is able to return to its original 
profile after chemotherapeutic and/or antibiotic intervention and if Clostridium 
difficile could be detected more often following therapy. We compared 
abundance (qPCR) and diversity (PCR-DGGE) of bacteria, Bacteroides, 
bifidobacteria, Clostridium cluster IV, Clostridium cluster XIVa and Clostridium 
difficile in faecal microbiota. 
Faecal microbial communities are composed of autochthonous gut members 
and by transient bacteria, consequently analysis of faecal samples may 
overestimate the actual composition of the GIT microbiota. However, faecal 
samples reflect shifts in populations [TURRONI et al., 2008]. 
We used type strains Bacteroides thetaiotaomicronT, Bifidobacterium longum 
ssp. longumT and Clostridium difficile as well as cloned sequences for 
quantification. However, a mixture of different strains for qPCR standards might 
be more accurate because some species might be preferentially amplified. 
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Therefore, qPCR results should be considered as semiquantitative and results 
focus mainly on comparative quantification. 
Diversity was assessed using the PCR-DGGE method. Several species 
possess more than one 16S rRNA operon such as E. coli IMBH 252/07 who 
forms 4 DGGE bands (FIG. 3). The limitations of DGGE in microbial analysis 
have been previously explored [MUYZER et al., 1998]. Nevertheless, DGGE 
analysis yields substantial information from very complex microbial communities 
[MUYZER et al., 1998].  
The group of patients receiving chemotherapy involved patients with and 
without antibiotic therapy. Many study participants had a longer history of 
different chemotherapeutic regimens. Two individuals had never received any 
cancer therapy before. Types of cancer chemotherapeutic therapy was variable 
as described in Material and Methods. Patient who did not receive any 
antibiotics showed similar alteration than those under antimicrobial therapy. Van 
Vliet et al., 2009 tested the effect of chemotherapy in vitro and showed a direct 
bacteriostatic effect of chemotherapeutics on bacterial growth. Despite this 
variability in clinical protocols results from changes in microbiota due to 
chemotherapeutic administration is remarkably homogenous.  
 
The majority previous studies on the effect of chemotherapy on human fecal 
microbiota used culture techniques [NYHLEN et al., 2002, STRINGER et al., 
2007]. Many studies focused on the colonization with pathogenic bacteria 
[SCHALK et al., 2009, VAN VLIET et al., 2009] in patients with cancer and 
chemotherapy-induced diarrhea [ABD EL-ATTI et al., 2009, STRINGER et al., 
2007].  
The mean proportion of Bacteroides in faecal samples was 27 ± 12% in 
chemotherapy patients and 23 ± 12% in healthy individuals. These results are 
not in agreement with the results of Nyhlèn et al., 2007 [NYHLEN et al., 2002] 
who showed increased counts of Bacteroides spp. of samples obtained during 
chemotherapy. Discrepancies in changes of the Bacteroides abundance might 
be due to differences in detection techniques, as Nyhlèn et al. used culture 
methods. Nyhlèn et al., 2007 also reported significantly increased counts of 
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yeast in patients, making it a focus for further research in immunocompromised 
patients. 
Our results show significant effects of chemotherapy and antibiotic treatment on 
intestinal microbiota. Despite high individual variations, we show a significantly 
lower absolute bacterial load in faeces of patients receiving chemotherapy in 
comparison to healthy controls. These findings are in line with data from van 
Vliet et al.,  2009 who reported 100-fold lower total bacterial numbers during 
chemotherapy treatment than in healthy controls. In addition to lower 
abundances of bacteria and determined bacterial subgroups, PCR-DGGE 
fingerprints indicate lower diversity of bacteria and Clostridium cluster XIVa in 
patients receiving chemotherapy. Faecal microbiota decreases after 
administration of chemotherapeutics. After the end of chemotherapeutic cycles 
the magnitude of microbiota recovers within a few days sometimes even 
showing a “rebound-effect”, supporting the hypothesis that the microbiota is 
able to recover after chemotherapeutic intervention. Relative numbers of 
Clostridium cluster IV and XIVa show great alterations due to 
chemotherapeutical interventions, while the genera Bacteroides and 
bifidobacteria seem to be less affected. Interestingly, patients receiving 
chemotherpeutics harboured significantly more Clostridium cluster IV but at 
lower diversity than controls. This suggests that different clusters of Clostridia 
contain species that are particularly vulnerable or even take advantage of 
disruption of community composition. The clostridial clusters are known to 
harbour a great diversity of phylogenetically loosely related bacteria. 
Emergence of Clostridium difficile may reflect changes in the community 
composition within the Clostridia. 
Further research needs to evaluate whether the observed changes in 
microbiota also play a role in the maintenance of the mucosal barrier functions, 
infection and inflammation [VAN VLIET et al., 2009]. 
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TABLES 
 
TABLE 1. Primers and TaqMan-probes targeting 16S rRNA coding regions of 
faecal bacteria for absolute and relative quantification used in this study. 
 
TABLE 2.  Primers for PCR-DGGE fingerprinting of 16S rRNA coding regions. 
 
FIGURES 
 
FIG. 1. Impact of medical treatment (chemotherapy and antibiotics) on human 
faecal microbiota. Absolute numbers of  Bacteroides (Bac), bifidobacteria (Bif), 
Clostridium cluster IV (Clept) and XIVa (Ccocc), Clostridium difficile (Cdiff) and 
unidentified bacteria analyzed by TaqMan-qPCR. ChT: Chemotherapy, Ab: 
Antibiotics F: fever, T: blood stem cell transplantation. Subject ON001 received 
chemotherapy before sampling. 
 
FIG. 2. Percentage of  Bacteroides (Bac), bifidobacteria (Bif), Clostridium 
cluster IV (Clept) and XIVa (Ccocc), Clostridium difficile (Cdiff) and unidentified 
bacteria of analyzed bacteria quantified by TaqMan-qPCR. 
 
FIG. 3. Changes of PCR-DGGE fingerprinting of 16S rRNA coding regions of 
dominant bacteria after chemotherapeutic treatment. Bands that get stronger or 
nearly disappear are indicated with arrows. SL: standardlane, A, B, C and D: 
ON001 receiving chemotherapy, E: healthy control. 
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FIG. 4. (A) Relative amount of faecal bacteria in patients receiving 
chemotherapy ± antibiotics (ON) in comparison to healthy individuals (C). 
Percentage of Bacteroides (bac), bifidobacteria (bif), Clostridium cluster IV 
(Clept) and cluster XIVa (Ccocc) in relation to detected bacteria. (B) 
Comparison of samplings during chemotherapeutic treatment with samplings 
without chemotherapeutic cycles. Percentage of Bacteroides (bac), 
bifidobacteria (bif), Clostridium cluster IV (Clept) and cluster XIVa (Ccocc) 
related to all analyzed bacteria. (C) Time points before Chemotherapy in 
comparison to time points after Chemotherapy.  
 
FIG. 5. Simpson and Shannon diversity indices derived from PCR-DGGE 
bandpattern of 16S rRNA coding regions of (A, B) bacteria, (C, D) Clostridium 
cluster IV and (E, F) Clostridium cluster XIVa. ON: Oncology patients receiving 
chemotherapy, C: healthy controls, ChT: sampling points during ChT, noChT: 
sampling points without chemotherapy, beforeChT: samplings before 
chemotherapy, afterChT: samplings after chemotherapy. 
 
FIG. 6. Principal component analysis (PCA) of Clostridium cluster IV DGGE 
fingerprints of 16S rRNA coding regions of dominant bacteria in faecal samples 
of patient receiving chemotherapy and healthy controls. Grey circles indicate 
time points after chemotherapy (O), black oval indicates timepoints before 
chemotherapy (T) and grey thin oval indicates the location of control samples 
(C) in the plot. 
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11.2 MANUSCRIPT – “CONSEQUENCES OF DIET AND AGEING FOR 
INDIVIDUAL SCFAS AND FAECAL MICROBIOTA” 
 
CONSEQUENCES OF DIET AND AGING FOR INDIVIDUAL SCFAS AND 
FAECAL MICROBIOTA 
 
Hippe, B, Zwielehner, J., Liszt, K., Lassl, C., Unger, F., Haslberger, A. G. 
 
ABSTRACT 
Short chain fatty acids (SCFAs) are end- and intermediate products of microbial 
breakdown of polysaccharides in the human gut. Especially butyric acid serves 
as major energy source for the gut epithelium and regulates inflammatory 
pathways and gene expression.  
The influence of microbiota and diet on inter individual differences in 
metabolites, particularly SCFAs, and colonic health is poorly understood. The 
aim of the study was to investigate whether the individual composition of 
microbiota affected by diet or age results in a specific difference in butyrate 
production. SCFAs were measured in faecal samples of elderly (n = 17; age = 
86 ± 8), young omnivores (n = 17; age = 24 ± 2.5) and young vegetarians (n = 
16; age = 26 ± 5) using HPLC-RI. Abundance of the Butyryl-CoA CoA-
transferase gene was analysed with gene specific real-time PCR applying three 
degenerate primer sets. Abundance of Archaea was estimated with a TaqMan 
real-time PCR system. 
Results:  
Butyric acid levels in faeces ranged between below detection limit (>0.0024 
µmol-g) up to 0.095 µmol-g faces. Vegetarians showed significantly lower butyric 
acid levels (68 %, p=0.06) compared to omnivores. Geriatric subject group 
showed lower levels of butyric acid compared to young omnivores, but not 
significant. 
The main short chain fatty acids found in faecal samples of most subjects were 
acetic acid, tartaric acid, lactic acid and propionic acid.  
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Butyryl-CoA CoA transferase gene levels showed higher abundances (3 times 
more, p=0.0001) in vegetarians than in omnivores. The average abundance of 
the Butyryl-CoA CoA transferase gene was 5,26 x 108±2,38 x 108 copies-µl in 
omnivores, 5.26 x 108 ± 2.38 x 108 copies-µl in elderly and 7.46 x 108 ± 2.29 x 
108 copies-µl in vegetarians.  
Archaea were nine times more abundant in omnivores, and in elderly (2.8 times 
more often) than in vegetarians.  
Conclusion: We show that age and diet influence the microbiota and the butyric 
acid abundance in faeces. Vegetarian diet favours growth of microbiota 
including SCFA producing bacteria in the gut lumen.  
 
INTRODUCTION 
The composition of GI microbiota is highly distinct between individuals 
[DETHLEFSEN et al., 2006] and different bacteria interact and influence each 
other in abundance and relation [NEISH, 2009]. These interactions and other 
factors influencing the intestinal microbiota and its establishment are related to 
food sources including delivery and nutrition [DUNCAN et al., 2007], life style 
factors, medical treatment and age [GUIGOZ et al., 2008] as well as genetic 
factors (Khachatryan et al. 2008).  
An important metabolic process of anaerobic colonic bacteria is their production 
of SCFAs. Strains that produce particularly high amounts of SCFAs from the 
breakdown of dietary fibre have been identified in the Bacteroides genus and -
amongst others- the Roseburia, Eubacteria and Butyrivibrio geni. Cell culture 
studies have indicated that the presence of butyrate at physiological 
concentrations enhances the growth of normal enterocytes and inhibits that of 
malignant ones [HINNEBUSCH et al., 2002]. Butyrate may have an 
anticarcinogenic and anti-inflammatory potential, affect the intestinal barrier and 
play a role in satiety and oxidative stress [HAMER et al., 2008]. Butyrate 
induces apoptosis in colorectal tumour cell lines, reduces metastasis, and 
protects from genotoxic carcinogens by enhancing expression of phase II 
detoxification enzymes [POOL-ZOBEL et al., 2007]. Acetate and butyrate 
promote methane production, while propionate formation is considered as a 
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competitive pathway for hydrogen use (Moss et al. 2000). Organic acid 
degradation depends on the presence of consortia of acetogenic bacteria and 
methanogenic Archaea (Stams et al. 2005). The majority of Archaea in the 
human GI-tract are related to Methanobrevibacter smithii (Dethlefsen,L et al. 
2006 ). 
Because of the rather low consumption of fermentable dietary fiber in today’s 
Central European diet the bacterial diversity in the lumen may vary, and with 
that the butyric acid concentrations. Our group has recently shown differences 
between the bacterial diversity in Vegetarians and Elderly compared to 
omnivores (Zwielehner et al. 2009; Liszt et al. 2009). Based on these previous 
results we investigate whether the individual composition of the microbiota 
results in a specific difference in butyric acid production and abundance.  
Faecal samples of young healthy individuals with omnivore or vegetarian diets 
as well as institutionalized elderly were analysed with HPLC-RI and TaqMan 
real-time PCR to quantify SCFAs and the abundance of the Butyryl-CoA CoA-
transferase gene.  
 
EXPERIMENTAL METHODS 
Study subjects 
DNA samples and subject group range were used from prior research carried 
out by our working group as published (Zwielehner et al. 2009, Liszt et al. 
2009). 
The geriatric group (Elderly) is formed by 17 institutionalized  subjects aged 86 
± 8 years BMI 21.75 ± 5.08, from a geriatric department in Vienna. The 
vegetarian diet group (Vegetarian) is formed by 16 young healthy subjects with 
a vegetarian or vegan diet, aged 26 ± 5 years with BMI 21.02 ± 2.71. Seventeen 
young healthy subjects aged 24 ± 2.5 years, BMI 22.68 ± 3.41 with a Central 
European diet form the mixed diet group (Omnivores).  
All volunteers were interviewed using a questionnaire assessing: age, gender, 
body height, weight, individual health status (including chronic or acute 
diseases and blood lipid levels), life-style aspects such as physical activity and 
dietary habits. 
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Group populations are gender balanced. Only non-pregnant probands with no 
diagnosed gastro-intestinal disease and no antibiotic or chemotherapeutic 
treatment up to three months prior to sampling were included in the study. All 
probands agreed to participate in the study and gave their informed consent. 
Approval was obtained from the Ethics committee of the city of Vienna. 
 
Faecal sample collection 
Faecal samples were collected from each participant individually and directly 
stored at -18°C. Faecal aliquots were taken for DNA extraction and SCFA 
analysis with HPLC.  
 
Quantification of functional genes and archaeal 16S rRNA gene with real-
time PCR 
Human colonic butyrate producers use Butyrylcoenzyme A CoA transferase 
[CHARRIER et al.] for the last step of butyrate formation. The CoA-transferase 
gene of the colonic bacterium Roseburia sp. A2-183 is similar to acetyl-CoA 
hydrolase as well as 4-hydroxybutyrate CoA-transferase sequences. Primer pair 
CoACT was described to target CoA transferase genes of: Roseburia sp. A2-
183, Desulfitobacterium hafniense (ZP_00098805, ZP_00099788), Clostridium 
kluyveri (P38942), Clostridium tetani (NP_781174), Archaeoglobus fulgidus 
(NP_069974) and Yersinia pestis (NP_405485); e.g. for CTFB primer pair: 
Clostridium beijerinckii (AF157306_3), Streptococcus pyogenes (NP_268527, 
NP_269686), Streptomyces coelicolor (T35020), Streptomyces sp. (T47110), E. 
coli (NP_416726) and Haemophilus influenzae (NP_438932) and e.g. for PCT 
primer pair: Clostridium perfringens (NP_561012), C. tetani (NP_781170, 
NP_781374), Bradyrhizobium japonicum (NP_767528), Listeria innocua 
(NP_471607) and Fusobacterium nucleatum (NP_603711). 
A ramped annealing approach was chosen for amplification of the functional 
genes with three degenerate primer sets as described in table 1 (Charrier et al. 
2006). Initial denaturation for 10 min at 94°C, then 35 cycles of denaturation  for 
30 s at 94°C, annealing with 20 s at 55°C, 5 s at 50°C, 5 s at 40°C, elongation 
for 1 min at 72°C, and a final extension for 5 min at 77°C. Archaeal 16S rRNA 
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gene sequences were amplified with a TaqMan real-time PCR as listed in table 
1. Conditions for real-time PCR with a 4 pmol primer and probe concentration 
were: Initial denaturation for 8 min at 95°C, 35 cycles of denaturation for 20 s at 
95°C, annealing at 20 s at 57°C and extension for 20s at 72°C, a final 
elongation for 1min at 72°C. 
 The different primer sets were applied to the stool samples and the PCR 
products quantified using the nano drop method. These PCR products served 
as standards for absolute and relative quantitation in real-time PCR. A relative 
quantitation was done for Archaea rRNA gene abundances to assess a possible 
correlation with Butyryl CoA CoA transferase gene abundances. 
 
 
Table 1: Primers and probes used for quantification of CoA-transferase genes 
and 16S rRNA genes of Archaea 
 
SCFA in faeces 
SCFA concentrations in facal specimens were measured according to the 
method of Huel-Mel Chen et al.1998. The faces were collected and stored 
frozen. After faces were thawed, 3g were homogenised in a Stomacher Lab-
Blender 400 for 2 minutes in 20 ml of 0.15 mmol/L H2SO4 in bidest-water. The 
homogenate was centrifuged at 6000 x g at 2 °C for 60 min. The supernatant 
Based target 
Organism/Gene 
Primer pairs 
or probe Sequence (5`-3`) Reference 
CoA Transferase 
based on  CoATD for  AAGGATCTCGGIRTICAYWSIGARATG 
C. Charrier et al. 
2006 
Roseburia sp. 
A2-183 
(AY796317) CoATD rev GAGGTCGTCICKRAAITYIGGRTGNGC   
        
CoA Transferase 
based on  CTFB for GTAAACTTIGGIRTIGGIYTNCCNAC 
C. Charrier et al. 
2006 
C. 
acetobutylicum 
(P23673) CTFB rev  AACAGTAACATCIAYRTGICCNCCNC   
        
CoA Transferase 
based on  PCT for GTAGGATTARRIACITWYRTIGAYCC 
C. Charrier et al. 
2006 
C. perfringens 
(NP_561012) PCT rev TCCACCACCATCRTARSARTCRAAYTG   
        
Archaea ARC787F F ATTAG ATACC CSBGT AGTCC  Y.Yu et al. 2005 
 
ARC915F 
TaqMan AGGAA TTGGC GGGGG AGCAC    
  ARC1059R R GCCAT GCACC WCCTC   
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fluid was then twice filtered through a micro filter syringe with 0.22 µm. The 
filtrate received no further treatment and was directly injected into the HPLC.  
 
SCFA Retention time (min.) detection Limit (µmol/g) 
Acetic acid      3.04 0.0010 
Tartaric acid    7,93 0.0016 
Lactic acid        6,86 0.0026 
Formic acid       7.52   
Fumaric acid      8.29   
Propionic acid    9.70 0.0043 
Butyric acid        11.98 0.0024 
Table 2: Retention times and limits under detection of measured short chain 
fatty acids. 
 
The standard calibration was determined from the average of five 0.95 mg/L 
injections for each standard acid solution as displayed in table 2. The HPLC 
apparatus (Dionex 3000) consisted of a mobilephase reservoir; a Dionex ICS 
3000 sp pump; an automatic sample injector, Dionex AS; a MetaCarb 67H 
organic acid chromatographic column, 300mm; a temperature control module; a 
refractive index detector; a chromatography control station and a system 
interface module. 
The mobile phase a 0.005 mMol solution of “ultra pure” sulphuric acid (VWR) in 
Milli-Q purified water (pH 3.1, background conductance <100 MS), was filtered 
through a 0.2 µm (Herba chemosan) membrane and degassed before use. 
Separation of SCFAs [HINNEBUSCH et al.] was best at a flow rate of 0.8 
ml/min and a column temperature of 36 °C. To regenerate the column, the 
column temperature was increased to 65 °C while washing with 25 mmol/L ultra 
pure sulphuric acid at a flow rate of 0.8 ml/min for 2 h.  
 
Analysed data and statistical interpretation 
Elementary statistical analysis (mean, standard deviation and coefficient of 
variation (F-test) was applied to the data (OriginPro8). Results for each group 
were normally distributed (Kolmogorov-Smirnov test). A two sample t-test was 
performed with OriginPro8. Correlations were calculated using Pearson’s linear 
regressions model and Spearman’s rank (OriginPro8). Data analysis of Ct 
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values and comparative correlation results were calculated using Rotorgene 
3000 and transferred to Excel.  Food frequency data collected with a food 
frequency questionnaire was analysed using the Chi-square approximation as 
implemented in SPSS15. All tests were double sided, p>0.05 was considered 
as significant. 
 
RESULTS 
Dietary analysis 
Exercise levels between the Vegetarian and Omnivore groups were 
comparable. Analysis of the participant’s dietary habits indicated similar 
consumption patterns of fruit and milk products in the groups. Omnivores stated 
significantly less frequent (Chi2 Test; p<0.027) consumption of vegetables than 
Vegetarians. Three of the Vegetarians assessed followed a vegan diet; all 
others followed a lacto-ovo vegetarian diet. The Omnivore group stated 
significantly less frequent (Chi2 Test; p<0.04) consumption of meat than Elderly 
probands and regular consumption of whole grain products several times a 
week. The Elderly of this study did not consume any whole grain products at all 
but received supplements with soluble fibre (Benfiber®, Novartis). 
 
Quantification of the Butyryl-CoA CoA-transferase gene 
Applying the CoATD primer set, Vegetarians (7.46 x 108 ± 2.29 x 108 copies-µl) 
had the highest abundance of the Butyryl-CoA CoA-transferase gene among all 
specimens. The abundance was significantly higher than for Omnivores (5,26 x 
108±2,38 x 108 copies-µl; p=0.0001) and Elderly (p=0.01). The abundance of this 
functional gene in Elderly (5.26 x 108 ± 2.38 x 108 copies-µl) showed the highest 
variation, being significantly higher than those found in Omnivores (p= 0.0007) 
but lower than in Vegetarians. 
Quantification with a CTFB primer yielded a gene abundance of 4.12 x 108 ± 
1.81 x 108 copies-µl for Omnivores, 4.6 x 108 ± 2.51 x 108 copies-µl for 
Vegetarians and 3.7 x 108 ± 1.89 x 108 copies-µl for Elderly. Applying the PCT 
primer pair, abundances of 8.61 x 108 ± 3.12 x 108 copies-µl for Omnivores, 8.53 
x 108 ± 5.28 x 108 copies-µl for Vegetarians and 6.55 x 108 ± 4.73 x 108 copies-µl 
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for Elderly were found. There were no significant differences, but a trend for 
lower abundances in Elderly and slightly higher abundances in Vegetarians.  
 
Figure 2: absolute concentration of Butyryl-CoA CoA-transferase gene 
abundance for the three primer pairs in group comparison 
 
Results for SCFAs 
Faecal concentrations of butyrate in specimens ranged from below detection 
limit up to 0.094 µmol g-1 faeces (wet weight). The average value for Omnivores 
was 0,023 µmol g-1 ± 0,027 µmol g-1 faeces, for Elderly 0,007 µmol g-1 ± 0,011 
µmol g-1 faeces and for Vegetarians 0,008 µmol g-1 ± 0,008 µmol g-1 faeces. 
Butyric acid concentrations found in the faeces of Omnivores were highest 
among all individuals, due to high inter-individual differences their values were 
significantly different only to Elderly. 
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Figure 3: Induvidual SCFA concentrations 
 
Relation of specimen specific Archaea  
Analysis of 16S rRNA genes showed that the mean abundance of Archaea in 
Omnivores was highest, being more than 9 times higher than for Vegetarians. 
Mean values of Elderly were 2.8 times those of Vegetarians. These differences 
were not significant due to high inter-individual differences.  
 
DISCUSSION 
Production and consumption of SCFAs is related by microbiota diversity which 
is influenced by diet, age, activity and other life style factors as well as host 
genetics. Our group has previously reported (bla) that vegetarians have 12% 
more bacterial DNA in their faeces than omnivores. Clostridium cluster IV and 
bifidobacteria showed no significant differences for vegetarians compared to 
omnivores. Bacteroide abundance was higher for vegetarians. To study the 
effects of changes in microbiota and their metabolites, such as SCFAs, we 
compared SCFAs in faeces using HPLC-RI, and quantified Butyryl-CoA CoA 
transferase genes using degenerated primer pairs in real-time PCR. Archaea 
were quantified because of their potential involvement in microbial consumption 
of SCFAs.  
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Methodological Aspects 
 
Real time PCR for CoA-transferase genes 
Degenerate primers were designed by [CHARRIER et al.] for a CoA-transferase 
gene found in Roseburia sp. A2-183. Charter et al. (2004) also analyzed the 
specificity of primers for different strains, as summarized in methods. 
As degenerate primers are mixtures of similar, but not identical, primers the 
specificity of the PCR amplification can be reduced. To avoid unspecific binding 
a ramped annealing approach was chosen. The specificity of the primer pairs 
was tested in real-time PCR by comparing the melt curve peaks to a negative 
control (Bacteroides tethaiotaomicron DSM 2079) and a positive control 
standard (specimen PCR product, including all identical target butyrl-CoA CoA 
transferase gene regions). Melt curve analysis and gel electrophoresis 
confirmed only a single PCR product. However, the three primer pairs used do 
not cover all butyrate producing bacteria, as described in Flint et al. (2006), 
because not all bacterial Butyryl CoA transferase gene loci are known. 
 
HPLC of SCFAs 
The RI detector and the organic acid chromatographic column have regularly 
been used to measure SCFAs. Detection limits are influenced by limited 
specimen volumes, their dilution and preparation.  
Weaver et al. (1997) describe butyrate concentrations in human faeces ranging 
from 11 to 25 mM and molar ratios of acetate to propionate to butyrate of 
between 48:29:23 and 70:15:15, with mean values of approximately 60:20:20 
(Weaver, Tangel et al. 1997; Hallert, Bjorck et al. 2003). We found mean SCFA 
ratios in Omnivores to be 63:13:24 and in Elderly to be 78:14:8. Vegetarians 
differed considerably from these values with molar ratios of 72:15:13. However, 
the in situ production of total colonic SCFAs is difficult to determine because 
more than 95% of the SCFAs are rapidly absorbed and metabolized by the host 
(McFall-Ngai et al. 2007). As a consequence, faecal concentrations of SCFAs 
are not necessarily representative of those in the more proximal colon, and can 
also be affected by intestinal transit time (Lewis and Heaton 1997).  
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Comparative real-time PCR of Archaea 
As different strains might have slightly different amplification efficiencies we 
express abundance of Archaea in % of control. Thus a real-time PCR product 
from one of the samples was used as a standard. 
 
 
CoA-transferase genes, SCFAs and Archaea in tested specimen groups 
The major differences observed between the measured groups (Omnivores, 
Elderly and Vegetarian) were the high butyric acid levels in Omnivores 
compared to Vegetarian individuals. The CoATD primer set amplification of 
butyric acid genes was highest in Vegetarians. This unexpected relationship 
might be attributable to a higher abundance of bacteria in vegetarians (Liszt et 
al. 2009), assuming that the bacterial surplus in those individuals carries genes 
that are amplified by this primer pair. Furthermore previous work carried out by 
our group showed that vegetarian’s species composition of the Clostridium 
cluster IV differed from the one found in omnivores (Liszt et al. 2009). It might 
well be that a vegetarian diet favours the abundance of butyrate-consuming 
microorganisms in the microbiota of the gut. Elderly had low butyric acid levels 
and low butyrl-CoA CoA transferase gene abundance, but showed the highest 
levels of acetic acid among all subjects. Zwielehner et al. (2009) reported the 
microbiota of elderly to be less diverse and less densely populated. Apparently 
the loss of diversity in the microbiota of elderly markedly affected the SCFA 
abundance, despite of high functional redundancy in the human GI microbiome 
(Lozupone et al. 2008). 
For Vegetarians the sequences amplified with CoATD primers were significantly 
more abundant than in all other individuals. Also the lower levels of butyric acid 
found in Vegetarians does not correspond to the Butyryl-CoA CoA transferase 
gene abundances. The targeted genes might not be equally expressed in all 
individuals and the butyric acid could be removed from the gut lumen by the gut 
mucosa and/or microorganisms. According to Stams et al. (2005) sulfate-
reducing bacteria easily outcompete methanogens for hydrogen and also grow 
much faster on propionate and butyrate than syntrophic consortia. Furthermore 
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not all bacteria might use the targeted gene Butyryl-CoA CoA transferase in the 
final steps of butyric acid production and the three primer pairs might not cover 
all butyrate producing bacteria (Flint et al. 2006). 
Up to 85% of humans carry Archaea in high abundances (Buck S 2006). The 
incidence of Archaea was highest in Omnivores. Omnivores also had the 
highest levels of Butyryl-CoA CoA transferase genes. Vegetarians had the 
lowest Archaea abundances and highest Butyryl-CoA CoA transferase gene 
abundances. Elderly were in between Omnivores and Vegetarians. In contrast 
to findings by Abell et al (2006) we observed a trend for high abundances of 
Archaea in samples with high butyric acid concentrations, however no linear 
correlations could be found, possibly due to enormous inter-individual variability. 
Our experiments showed enormous variability among Elderly individuals with 
their data points being distributed within the ranges of young Vegetarians and 
Omnivores. One explanation might be a highly variable dietary behaviour 
throughout their lives, in some persons being predominantly vegetarians.  
Elderly Austrians are reported to consume 78 g meat day-1, whereas adult 
omnivores are reported to consume 103 g day-1, 60 g more than 
recommended. The overall protein uptake in vegetarians matches the D-A-CH 
recommendations (0.8g kg-1 body weight). The major difference in diets might 
thus be the differential uptake of nitrogen from dietary protein (Austrian Nutrition 
Report 2009). Approximately 10% of dietary protein reaches the colon (Schmidt 
R. et al. 2007). According to the 2009 Austrian Nutrition Report fibre 
consumption is staggered as vegetarians > omnivores > elderly. All Elderly in 
our geriatric subject group received prebiotic supplementation.  
By combining molecular analyses with HPLC of SCFAs as well as a food and 
activity questionnaire, we demonstrate the profound effects of diet and ageing 
on the human gut microbiome. These results demonstrate that faecal butyric 
acid levels do not correlate with the abundance of the Butyryl-CoA CoA-
transferase gene. The complexity of the colonic environment renders it difficult 
to use single metabolites such as butyric acid as indicators for colonic health. 
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Figure 4: Group Specific Concentration Trends in 100% total of each 
measurement 
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Changes in human faecal microbiota due to chemotherapy analyzed by TaqMan‐PCR and 
PCR‐DGGE fingerprinting
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BACKGROUND: The composition of the 
gastrointestinal microbiota i s highly distinctive between 
individuals and  the majority of sequences seem to be 
unique to some individuals (Turnbaugh et al.,  2009). 
Correlations between  the gastrointestinal microbiota and 
diseases like allergenicity (Shreiner et al., 2008), 
inflammatory bowel diseases (Sokol et al.,  2006) and 
individual dispositions such as obesity (Zhang et al., 2009) 
have been discussed. Specific genera  have been 
associated with specific health benefits such as short 
chain fatty acid production by species of the genera 
Clostridium , Eubacter ium and Fusobacterium. 
Gastrointestinal disturbances (e.g.: diarrhea) are often 
induced in response to cancer treatments such as 
chemotherapy or  radiation (Abd El‐Atti et al.,  2009). 
Disturbances in the homeostasis of microbiota are 
discussed to favor severely pathogenic bacteria such as 
Clostridium  difficile .
OBJECTIVES: The purpose of this study was to 
investigate changes within the GI microbiota  in response 
to chemotherapy against different kinds of cancer.  We 
assessed diversity  and abundance of bacteria,  
Bacteroides, bifidobacteria, Clostridium cluster IV and 
XIVa and Clostr idium difficile.
SUBJECTS: Faeces, food frequency questionnaires and 
case report  forms of 9 ambulant patients (ON, 60 ± 11 
years) receiving  chemotherapy ± antibiotic treatment  
were collected and analyzed at four sampling  points 
before or after the onset of treatment in comparison to 9 
gender‐, age‐ and lifestyle‐matched healthy individuals 
(C, 53 ± 18 years).
METHODS: We targeted 16S rRNA genes of bacteria, 
Bacteroides, bifidobacteria, Clostridium cluster IV and 
XIVa as well as Clostridium difficile with TaqMan‐qPCR.  
We assessed diversity and temporal stability of bacteria  
and Clostridium clusters IV and XIVa at  the four sampling 
points using denaturing gradient gel electrophoresis 
(DGGE) fingerprinting.
RESULTS & DISCUSSION: 
•Faecal microbiota of patients receiving chemotherapy ( ± antibiot ics) decreases 
significantly after cycles of chemotherapy and in comparison to healthy controls.
•After the end of chemotherapeutic cycles the magnitude of microbiota recovers within a 
few days sometimes even showing a “rebound‐effect”.
•All bacterial subgroups show high intra‐ and interindividual variations.
•The chemotherapeutical treatment has marginally affected the genus Bacteroides while 
the genera Clostridium cluster IV and XIVa seem  to be more sensitive to chemotherapy and 
antibiotic treatment.
•A decreased diversity of bacteria  and Clostridium cluster XIVawas observed in response 
to medical treatment compared to healthy individuals. 
•The incidence of Clostridium diffici le in subject ON009 results or is a result of a  decrease 
of the genera  bifidobacteria and Clostridium cluster IV.
•Monitoring of microbiota  using  qPCR an PCR‐DGGE might be an easy  and adequate tool 
to guide decisions  for or against probiotic intervention.
Figure 2: Absolut numbers of  Bacteroides (Bac), bifidobacteria (Bi f), Clostridium cluster
IV (Clept) and XIVa (Ccocc), Clostridium difficile (Cdiff) and unidenti fied bacter ia
analyzed by TaqMan‐qPCR. ChT: Chemotherapy, Ab: Antibiotics F: fever, T: blood stem
cel l transplantation.  Subject ON001 received chemotherapy before sampling.
Figure 3: Percentage of  Bacteroides (Bac), bifidobacteria (Bif), Clostridium cluster IV
(Clept) and XIVa (Ccocc), Clostridium diffi ci le (Cdi ff) and unidentified bacteria of 
analyzed bacteria quantified by TaqMan‐qPCR.          Clostridium difficile
Figure 1: PCR‐DGGE fingerprinting of 16S rRNA coding
regions of bacteria. SL: standardlane,  A, B, C and D: 
ON001 receiving chemotherapy, E: healthy control.
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CHANGES IN HUMAN FAECAL MICROBIOTA DUE TO CHEMOTHERAPY 
ANALYZED BY TAQMAN-PCR AND PCR-DGGE 
 
C. Laßl, J. Zwielehner, K. Liszt, B. Hippe, A. G. Haslberger 
Department of Nutrition, University of Vienna 
 
We analyzed the diversity and abundance of Bacteroides spp., Bifidobacteria, 
Clostridium clusters IV and XIVa as well as Clostridium difficile in microbiota of 
individuals undergoing chemotherapeutic treatment. 
Faeces of ambulant leukemic patients receiving chemotherapy ± antibiotic 
treatment were analyzed before and after the onset of treatment in comparison 
to gender-, age- and lifestyle-matched healthy controls. Diet was assessed with 
a food frequency questionnaire. Faecal samples were analyzed with 
quantitative TaqMan-PCR and qualitative PCR-DGGE fingerprinting of 16S 
rRNA coding regions. 
A decrease of overall bacteria and Clostridium clusters IV and XIVa was 
observed in response to chemotherapy. The progression of the community 
changes within the gut microbiota showed high individual variations at the four 
time points investigated, but an overall increase of abundance of Clostridium 
difficile could be observed in leukaemia patients compared to healthy controls. 
Conclusion: Overall changes of community composition within the human 
microbiota in response to chemotherapeutic treatment might affect the 
incidence of Clostridium difficile in leukemia patients. 
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